Usual	JJ	O
adult	NN	B-WHO
dose	VBD	O
4	CD	B-DOS
-	:	O
8	CD	B-DOS
mg	JJ	B-UNIT
daily	RB	B-FREQ
.	.	O

One	CD	B-DOS
or	CC	O
two	CD	B-DOS
capsules	NNS	B-UNIT
every	DT	B-FREQ
four	CD	I-FREQ
hours	NNS	O-FREQ
.	.	O

The	DT	O
dosage	NN	O
regimen	NNS	O
for	IN	O
TriNessa®	NNP	O
for	IN	O
treatment	NN	O
of	IN	O
facial	JJ	O
acne	NN	O
,	,	O
as	IN	O
available	JJ	O
in	IN	O
a	DT	O
blister	NN	O
card	NN	O
with	IN	O
a	DT	O
tablet	NN	O
dispenser	NN	O
,	,	O
utilizes	VBZ	O
a	DT	O
21	CD	O
-	:	O
day	NN	O
active	JJ	O
and	CC	O
a	DT	O
7	CD	O
-	:	O
day	NN	O
placebo	NN	O
schedule	NN	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
is	VBZ	O
300	CD	B-DOS
mg	NN	B-UNIT
by	IN	O
subcutaneous	JJ	O
injection	NN	O
at	IN	O
Weeks	NNP	O
0	CD	O
,	,	O
1	CD	O
,	,	O
2	CD	O
,	,	O
3	CD	O
,	,	O
and	CC	O
4	CD	O
followed	VBN	O
by	IN	O
300	CD	B-DOS
mg	NNS	B-UNIT
every	DT	B-FREQ
4	CD	I-FREQ
weeks	NNS	O-FREQ
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
clinically	RB	O
important	JJ	O
hypotension	NN	O
in	IN	O
the	DT	O
setting	NN	O
of	IN	O
anesthesia	NN	O
is	VBZ	O
an	DT	O
initial	JJ	O
dose	NN	O
of	IN	O
5	CD	B-DOS
to	TO	O
10	CD	B-DOS
mg	NNS	B-UNIT
administered	VBN	O
by	IN	O
intravenous	JJ	O
bolus	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
one	CD	B-DOS
CLEOCIN	NNP	B-UNIT
Vaginal	NNP	I-UNIT
Ovule	NNP	O-UNIT
(	(	O
containing	VBG	O
clindamycin	NN	O
phosphate	NN	O
equivalent	NN	O
to	TO	O
100	CD	B-DOS
mg	NNS	B-UNIT
clindamycin	VBP	O
per	IN	O
2.5	CD	B-DOS
g	JJ	B-UNIT
suppository	NN	O
)	)	O
intravaginally	RB	O
per	IN	B-FREQ
day	NN	O-FREQ
,	,	O
preferably	RB	O
at	IN	O
bedtime	NN	O
,	,	O
for	IN	O
3	CD	B-DUR
consecutive	JJ	I-DUR
days	NNS	O-DUR
.	.	O

Based	VBN	O
on	IN	O
clinical	JJ	O
studies	NNS	O
,	,	O
the	DT	O
average	JJ	O
prescribed	JJ	O
adult	JJ	B-WHO
daily	JJ	B-FREQ
dose	NN	O
of	IN	O
sevelamer	JJ	O
carbonate	NN	O
is	VBZ	O
approximately	RB	O
7.2	CD	B-DOS
g	NNS	B-UNIT
per	IN	B-FREQ
day	NN	O-FREQ
.	.	O

The	DT	O
initial	JJ	O
dosage	NN	O
of	IN	O
prednisolone	NN	O
sodium	NN	O
(	(	O
prednisolone	JJ	O
sodium	NN	O
phosphate	NN	O
oral	JJ	O
solution	NN	O
)	)	O
phosphate	NN	O
,	,	O
USP	NNP	O
,	,	O
oral	JJ	O
solution	NN	O
may	MD	O
vary	VB	O
from	IN	O
5	CD	B-DOS
mL	NNS	B-UNIT
to	TO	O
60	CD	B-DOS
mL	NN	B-UNIT
(	(	O
5	CD	B-DOS
to	TO	O
60	CD	B-DOS
mg	NN	B-UNIT
prednisolone	NN	O
base	NN	O
)	)	O
per	IN	B-FREQ
day	NN	O-FREQ
depending	VBG	O
on	IN	O
the	DT	O
specific	JJ	O
disease	NN	O
entity	NN	O
being	VBG	O
treated	VBN	O
.	.	O

In	IN	O
patients	NNS	B-WHO
who	WP	I-WHO
tolerate	VBP	I-WHO
the	DT	I-WHO
full	JJ	I-WHO
intravenous	JJ	I-WHO
dose	NN	O-WHO
(	(	O
15	CD	B-DOS
mg	NN	B-UNIT
)	)	O
,	,	O
initiate	JJ	O
Lopressor	NNP	O
tablets	NNS	O
,	,	O
50	CD	B-DOS
mg	NN	B-UNIT
every	DT	B-FREQ
6	CD	I-FREQ
hours	NNS	O-FREQ
,	,	O
15	CD	O
minutes	NNS	O
after	IN	O
the	DT	O
last	JJ	O
intravenous	JJ	O
dose	NN	O
and	CC	O
continue	VB	O
for	IN	O
48	CD	O
hours	NNS	O
.	.	O

Apply	VB	O
a	DT	O
thin	JJ	O
film	NN	O
of	IN	O
Clindamycin	NNP	O
Phosphate	NNP	O
Topical	NNP	O
Solution	NNP	O
twice	RB	B-FREQ
daily	RB	O-FREQ
to	TO	O
affected	JJ	O
area	NN	O
.	.	O

Adults	NNS	B-WHO
:	:	O
The	DT	O
usual	JJ	O
dosage	NN	O
for	IN	O
persons	NNS	B-WHO
13	CD	I-WHO
years	NNS	I-WHO
of	IN	I-WHO
age	NN	I-WHO
and	CC	I-WHO
over	NN	O-WHO
is	VBZ	O
1	CD	B-DOS
ml	NN	B-UNIT
Buprenex	NNP	O
(	(	O
buprenorphine	NN	O
)	)	O
(	(	O
0.3	CD	B-DOS
mg	RB	B-UNIT
buprenorphine	NN	O
)	)	O
given	VBN	O
by	IN	O
deep	JJ	O
intramuscular	NN	O
or	CC	O
slow	VB	O
(	(	O
over	IN	O
at	IN	O
least	JJS	O
2	CD	O
minutes	NNS	O
)	)	O
intravenous	JJ	O
injection	NN	O
at	IN	O
up	IN	O
to	TO	O
6	CD	O
-	:	O
hour	NN	O
intervals	NNS	O
,	,	O
as	IN	O
needed	VBN	O
.	.	O

The	DT	O
initial	JJ	O
dosage	NN	O
of	IN	O
DELTASONE	NNP	O
Tablets	NNP	O
may	MD	O
vary	VB	O
from	IN	O
5	CD	B-DOS
mg	NNS	B-UNIT
to	TO	O
60	CD	B-DOS
mg	NN	B-UNIT
of	IN	O
prednisone	NN	O
per	IN	B-FREQ
day	NN	O-FREQ
depending	VBG	O
on	IN	O
the	DT	O
specific	JJ	O
disease	NN	O
entity	NN	O
being	VBG	O
treated	VBN	O
.	.	O

Apply	NNP	O
Tolak	NNP	O
Cream	NNP	O
once	RB	B-FREQ
daily	RB	O-FREQ
in	IN	O
an	DT	O
amount	NN	O
sufficient	NN	O
to	TO	O
cover	VB	O
the	DT	O
lesions	NNS	O
of	IN	O
the	DT	O
face	NN	O
,	,	O
ears	NNS	O
,	,	O
and	CC	O
/	NNP	O
or	CC	O
scalp	VBN	O
with	IN	O
a	DT	O
thin	JJ	O
film	NN	O
,	,	O
using	VBG	O
the	DT	O
fingertips	NNS	O
to	TO	O
gently	RB	O
massage	VB	O
the	DT	O
medication	NN	O
uniformly	RB	O
into	IN	O
the	DT	O
skin	NN	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
SOLODYN	NNP	O
is	VBZ	O
approximately	RB	O
1	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
kg	NNS	O
once	RB	B-FREQ
daily	RB	O-FREQ
for	IN	O
12	CD	B-DUR
weeks	NNS	O-DUR
.	.	O

A	DT	O
dosage	NN	O
of	IN	O
0.024	CD	B-DOS
to	TO	O
0.034	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
kg	JJ	O
/	NNP	B-FREQ
day	NN	O-FREQ
,	,	O
6	CD	B-FREQ
to	TO	O
7	CD	B-FREQ
times	NNS	I-FREQ
a	DT	I-FREQ
week	NN	O-FREQ
,	,	O
is	VBZ	O
recommended	VBN	O
.	.	O

The	DT	O
dosage	NN	O
range	NN	O
is	VBZ	O
0.2	CD	B-DOS
mg	NN	B-UNIT
to	TO	O
0.8	CD	B-DOS
mg	NNS	B-UNIT
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
ELMIRON®	NNP	O
is	VBZ	O
300	CD	B-DOS
mg	JJ	B-UNIT
/	NNP	B-FREQ
day	NN	O-FREQ
taken	VBN	O
as	IN	O
one	CD	B-DOS
100	CD	O-DOS
mg	NN	B-UNIT
capsule	NN	O-UNIT
orally	RB	O
three	CD	B-FREQ
times	NNS	I-FREQ
daily	RB	O-FREQ
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
ZYFLO	NNP	O
CR	NNP	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
asthma	NN	O-WHO
is	VBZ	O
two	CD	B-DOS
600	CD	O-DOS
mg	NN	B-UNIT
extended	VBN	O
-	:	O
release	NN	O
tablets	NNS	O
twice	RB	B-FREQ
daily	RB	O-FREQ
,	,	O
within	IN	O
one	CD	O
hour	NN	O
after	IN	O
morning	NN	O
and	CC	O
evening	NN	O
meals	NNS	O
,	,	O
for	IN	O
a	DT	O
total	JJ	O
daily	JJ	B-FREQ
dose	NN	O
of	IN	O
2400	CD	B-DOS
mg.	JJ	B-UNIT
Tablets	NNS	O
should	MD	O
not	RB	O
be	VB	O
chewed	VBN	O
,	,	O
cut	VBD	O
or	CC	O
crushed	VBN	O
.	.	O

The	DT	O
maximum	NN	O
recommended	VBD	O
dose	NN	O
is	VBZ	O
four	CD	B-DOS
tablets	NNS	B-UNIT
(	(	O
one	CD	B-DOS
in	IN	O
the	DT	O
morning	NN	O
,	,	O
one	CD	B-DOS
in	IN	O
the	DT	O
mid	NN	O
-	:	O
afternoon	NN	O
and	CC	O
two	CD	B-DOS
at	IN	O
bedtime	NN	O
)	)	O
daily	RB	B-FREQ
.	.	O

The	DT	O
range	NN	O
of	IN	O
initial	JJ	O
doses	NNS	O
is	VBZ	O
0.11	CD	B-DOS
to	TO	O
1.6	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
kg	JJ	O
/	NNP	B-FREQ
day	NN	O-FREQ
in	IN	O
3	CD	B-DOS
or	CC	O
4	CD	B-DOS
divided	VBN	B-UNIT
doses	NNS	O-UNIT
(	(	O
3.2	CD	B-DOS
to	TO	O
48	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
m²bsa	JJ	O
/	NNP	B-FREQ
day	NN	O-FREQ
)	)	O
.	.	O

The	DT	O
usual	JJ	O
dose	NN	O
is	VBZ	O
2	CD	B-DOS
mg	NN	B-UNIT
(	(	O
1	CD	B-DOS
/	RB	O
2	CD	B-DOS
/	JJ	O
18	CD	B-DOS
tablet	NN	B-UNIT
)	)	O
two	CD	B-FREQ
or	CC	O
three	CD	B-FREQ
times	NNS	I-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
,	,	O
adjusted	VBN	O
as	IN	O
necessary	JJ	O
to	TO	O
the	DT	O
size	NN	O
and	CC	O
response	NN	O
of	IN	O
the	DT	O
patient	NN	O
.	.	O

The	DT	O
recommended	VBN	O
adult	NN	B-WHO
dose	NN	O
for	IN	O
most	JJS	O
patients	NNS	O
is	VBZ	O
one	CD	B-DOS
(	(	O
1	CD	B-DOS
)	)	O
AMRIX	$	O
15	CD	B-DOS
mg	NN	B-UNIT
capsule	NN	O-UNIT
taken	VBN	O
once	RB	B-FREQ
daily	JJ	O-FREQ
.	.	O

The	DT	O
usual	JJ	O
dose	NN	O
of	IN	O
MAXZIDE	NNP	O
-	:	O
25	CD	B-DOS
MG	NNP	B-UNIT
is	VBZ	O
one	CD	B-DOS
or	CC	O
two	CD	B-DOS
tablets	NNS	B-UNIT
daily	RB	B-FREQ
,	,	O
given	VBN	O
as	IN	O
a	DT	O
single	JJ	B-DOS
dose	NN	B-UNIT
,	,	O
with	IN	O
appropriate	JJ	O
monitoring	NN	O
of	IN	O
serum	JJ	O
potassium	NN	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
adult	NN	B-WHO
dose	NN	O
for	IN	O
all	DT	O
QUESTRAN	NNP	O
powdered	VBN	O
products	NNS	O
(	(	O
QUESTRAN	NNP	O
Powder	NNP	O
and	CC	O
QUESTRAN	NNP	O
Light	NNP	O
)	)	O
is	VBZ	O
one	CD	B-DOS
packet	NN	B-UNIT
or	CC	O
one	CD	B-DOS
level	NN	B-UNIT
scoopful	JJ	O-UNIT
once	RB	B-FREQ
or	CC	O
twice	VB	B-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
SAVAYSA	NNP	O
is	VBZ	O
60	CD	B-DOS
mg	NN	B-UNIT
taken	VBN	O
orally	RB	O
once	RB	B-FREQ
daily	JJ	O-FREQ
.	.	O

The	DT	O
recommended	JJ	O
daily	JJ	B-FREQ
dosage	NN	O
is	VBZ	O
180	CD	B-DOS
mg	NN	B-UNIT
to	TO	O
240	CD	B-DOS
mg	NNS	B-UNIT
Inderal	JJ	O
per	IN	B-FREQ
day	NN	O-FREQ
in	IN	O
divided	JJ	O
doses	NNS	O
.	.	O

The	DT	O
usual	JJ	O
total	JJ	O
daily	JJ	B-FREQ
dose	NN	O
of	IN	O
ZOSYN	NNP	O
for	IN	O
adults	NNS	B-WHO
is	VBZ	O
3.375	CD	B-DOS
g	NN	B-UNIT
every	DT	B-FREQ
six	CD	I-FREQ
hours	NNS	O-FREQ
totaling	VBG	O
13.5	CD	B-DOS
g	NN	B-UNIT
(	(	O
12	CD	B-DOS
g	NN	B-UNIT
piperacillin	NN	O
/	VBD	O
1.5	CD	B-DOS
g	NNS	B-UNIT
tazobactam	NN	O
)	)	O
.	.	O

The	DT	O
usual	JJ	O
adult	NN	B-WHO
dosage	NN	O
is	VBZ	O
one	CD	B-DOS
tablet	NN	B-UNIT
every	DT	B-FREQ
6	CD	I-FREQ
hours	NNS	O-FREQ
as	IN	O
needed	VBN	O
for	IN	O
pain	NN	O
.	.	O

The	DT	O
usual	JJ	O
adult	NN	B-WHO
dosage	NN	O
is	VBZ	O
one	CD	B-DOS
tablespoonful	NN	B-UNIT
every	DT	B-FREQ
4	CD	O-FREQ
to	TO	O
6	CD	B-FREQ
hours	NNS	O-FREQ
as	IN	O
needed	VBN	O
for	IN	O
pain	NN	O
.	.	O

The	DT	O
recommended	JJ	O
initial	JJ	O
dose	NN	O
for	IN	O
weekly	JJ	O
intravenous	JJ	O
administration	NN	O
is	VBZ	O
1000	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
m²	NN	O
of	IN	O
body	NN	O
surface	JJ	O
area	NN	O
at	IN	O
weekly	JJ	O
intervals	NNS	O
for	IN	O
the	DT	O
first	JJ	O
two	CD	O
courses	NNS	O
(	(	O
weeks	NNS	O
)	)	O
.	.	O

The	DT	O
recommended	VBN	O
prophylactic	JJ	O
dose	NN	O
of	IN	O
RYANODEX	NNP	O
is	VBZ	O
2.5	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
kg	NN	O
administered	VBD	O
intravenously	RB	O
over	IN	O
a	DT	O
period	NN	O
of	IN	O
at	IN	O
least	JJS	O
1	CD	O
minute	NN	O
,	,	O
starting	VBG	O
approximately	RB	O
75	CD	O
minutes	NNS	O
prior	RB	O
to	TO	O
surgery	NN	O
.	.	O

Active	JJ	O
Duodenal	NNP	O
Ulcer	NNP	O
—	VBZ	O
The	DT	O
recommended	JJ	O
oral	JJ	O
dosage	NN	O
for	IN	O
adults	NNS	B-WHO
is	VBZ	O
300	CD	B-DOS
mg	NN	B-UNIT
once	RB	B-FREQ
daily	RB	O-FREQ
at	IN	O
bedtime	NN	O
.	.	O

The	DT	O
recommended	JJ	O
initial	JJ	O
dose	NN	O
of	IN	O
Nascobal	NNP	O
(	(	O
cyanocobalamin	NN	O
)	)	O
Nasal	NNP	O
Spray	NNP	O
is	VBZ	O
one	CD	B-DOS
spray	NN	B-UNIT
(	(	O
500	CD	B-DOS
mcg	NN	B-UNIT
)	)	O
administered	VBD	O
in	IN	O
ONE	CD	O
nostril	NN	O
once	RB	B-FREQ
weekly	JJ	O-FREQ
.	.	O

The	DT	O
usual	JJ	O
adult	NN	B-WHO
dosage	NN	O
of	IN	O
Norpace	NNP	O
(	(	O
disopyramide	JJ	O
phosphate	NN	O
)	)	O
or	CC	O
Norpace	NNP	O
(	(	O
disopyramide	JJ	O
phosphate	NN	O
)	)	O
CR	NNP	O
is	VBZ	O
400	CD	B-DOS
to	TO	O
800	CD	B-DOS
mg	NNS	B-UNIT
per	IN	B-FREQ
day	NN	O-FREQ
given	VBN	O
in	IN	O
divided	JJ	O
doses	NNS	O
.	.	O

Usual	JJ	O
Dosage	NNP	O
in	IN	O
Adults	NNP	B-WHO
:	:	O
To	TO	O
lower	VB	O
the	DT	O
risk	NN	O
of	IN	O
constipation	NN	O
,	,	O
LOTRONEX	NNP	O
(	(	O
alosetron	VB	O
hydrochloride	NN	O
)	)	O
should	MD	O
be	VB	O
started	VBN	O
at	IN	O
a	DT	O
dosage	NN	O
of	IN	O
0.5	CD	B-DOS
mg	NN	B-UNIT
twice	RB	B-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
.	.	O

10	CD	B-DOS
mL	NN	B-UNIT
every	DT	B-FREQ
4	CD	O-FREQ
to	TO	O
6	CD	B-FREQ
hours	NNS	O-FREQ
,	,	O
not	RB	O
to	TO	O
exceed	VB	O
4	CD	B-DOS
doses	NNS	B-UNIT
(	(	O
40	CD	B-DOS
mL	NN	B-UNIT
)	)	O
in	IN	O
24	CD	O
hours	NNS	O
.	.	O

The	DT	O
initial	JJ	O
dosage	NN	O
of	IN	O
Parlodel	NNP	O
SnapTabs®	NNP	O
in	IN	O
adults	NNS	B-WHO
is	VBZ	O
½	JJ	B-DOS
to	TO	O
one	CD	B-DOS
2½	CD	O-DOS
mg	NN	B-UNIT
scored	VBD	I-UNIT
tablet	JJ	O-UNIT
daily	JJ	B-FREQ
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
20	CD	B-DOS
mg	JJ	B-UNIT
twice	RB	B-FREQ
daily	RB	O-FREQ
.	.	O

The	DT	O
usual	JJ	O
starting	VBG	O
dose	NN	O
of	IN	O
NARDIL	NNP	O
is	VBZ	O
one	CD	B-DOS
tablet	NN	B-UNIT
(	(	O
15	CD	B-DOS
mg	NN	B-UNIT
)	)	O
three	CD	B-FREQ
times	NNS	I-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
.	.	O

Apply	VB	O
a	DT	O
thin	JJ	O
film	NN	O
of	IN	O
EPIDUO	NNP	O
gel	NN	O
to	TO	O
affected	JJ	O
areas	NNS	O
of	IN	O
the	DT	O
face	NN	O
and	CC	O
/	NN	O
or	CC	O
trunk	NN	O
once	RB	B-FREQ
daily	RB	O-FREQ
after	IN	O
washing	VBG	O
.	.	O

Adults	NNS	B-WHO
:	:	O
15	CD	B-DOS
to	TO	O
60	CD	B-DOS
mg	NN	B-UNIT
every	DT	B-FREQ
4	CD	O-FREQ
to	TO	O
6	CD	B-FREQ
hours	NNS	O-FREQ
(	(	O
usual	JJ	O
adult	NN	B-WHO
dose	NN	O
,	,	O
30	CD	B-DOS
mg	NN	B-UNIT
)	)	O
.	.	O

To	TO	O
receive	VB	O
the	DT	O
full	JJ	O
dose	NN	O
of	IN	O
medication	NN	O
,	,	O
SPIRIVA	NNP	O
RESPIMAT	NNP	O
must	MD	O
be	VB	O
administered	VBN	O
as	IN	O
two	CD	B-DOS
inhalations	NNS	B-UNIT
once	RB	B-FREQ
-	:	O
daily	NN	B-FREQ
.	.	O

Instill	NNP	O
one	CD	B-DOS
to	TO	O
two	CD	B-DOS
drops	NNS	B-UNIT
into	IN	O
the	DT	O
conjunctival	JJ	O
sac	NN	O
two	CD	B-FREQ
to	TO	O
four	CD	B-FREQ
times	NNS	I-FREQ
daily	RB	O-FREQ
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
BEXTRA	NNP	O
Tablets	NNP	O
for	IN	O
the	DT	O
relief	NN	O
of	IN	O
the	DT	O
signs	NNS	O
and	CC	O
symptoms	NNS	O
of	IN	O
arthritis	NN	O
is	VBZ	O
10	CD	B-DOS
mg	NN	B-UNIT
once	RB	B-FREQ
daily	RB	O-FREQ
.	.	O

The	DT	O
usual	JJ	O
adult	NN	B-WHO
dosage	NN	O
is	VBZ	O
one	CD	B-DOS
tablespoonful	NN	B-UNIT
(	(	O
15	CD	B-DOS
mL	NN	B-UNIT
)	)	O
every	DT	B-FREQ
four	CD	I-FREQ
to	TO	I-FREQ
six	CD	I-FREQ
hours	NNS	O-FREQ
as	IN	O
needed	VBN	O
for	IN	O
pain	NN	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
of	IN	O
Oleptro	NNP	O
is	VBZ	O
150	CD	B-DOS
mg	NN	B-UNIT
once	RB	B-FREQ
daily	JJ	O-FREQ
in	IN	O
adults	NNS	B-WHO
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
Abciximab	NNP	O
in	IN	O
adults	NNS	B-WHO
is	VBZ	O
a	DT	O
0.25	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
kg	VBZ	O
intravenous	JJ	B-DOS
bolus	NN	B-UNIT
administered	VBD	O
10	CD	O
-	:	O
60	CD	O
minutes	NNS	O
before	IN	O
the	DT	O
start	NN	O
of	IN	O
PCI	NNP	O
,	,	O
followed	VBN	O
by	IN	O
a	DT	O
continuous	JJ	O
intravenous	JJ	O
infusion	NN	O
of	IN	O
0.125	CD	B-DOS
μg	JJ	B-UNIT
/	NNP	O
kg	NN	O
/	NNP	O
min	NN	O
(	(	O
to	TO	O
a	DT	O
maximum	NN	O
of	IN	O
10	CD	O
μg	JJ	O
/	NNP	O
min	NN	O
)	)	O
for	IN	O
12	CD	O
hours	NNS	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
for	IN	O
Parkinson	NNP	O
's	POS	O
disease	NN	O
is	VBZ	O
0.25	CD	B-DOS
mg	NN	B-UNIT
three	CD	B-FREQ
times	NNS	I-FREQ
daily	RB	O-FREQ
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
Astelin	NNP	O
Nasal	NNP	O
Spray	NNP	O
in	IN	O
adults	NNS	B-WHO
and	CC	I-WHO
adolescent	JJ	I-WHO
patients	NNS	O-WHO
12	CD	O
years	NNS	O
and	CC	O
older	JJR	O
with	IN	O
seasonal	JJ	O
allergic	JJ	O
rhinitis	NN	O
is	VBZ	O
one	CD	B-DOS
or	CC	O
two	CD	B-DOS
sprays	NNS	B-UNIT
per	IN	O
nostril	JJ	O
twice	JJ	B-FREQ
daily	RB	O-FREQ
.	.	O

Initiate	NNP	O
treatment	NN	O
with	IN	O
a	DT	O
dose	NN	O
of	IN	O
1000	CD	B-DOS
mg	NN	B-UNIT
once	RB	B-FREQ
daily	RB	O-FREQ
.	.	O

Daily	JJ	B-FREQ
doses	NNS	O
of	IN	O
ZOHYDRO	NNP	O
ER	NNP	O
,	,	O
a	DT	O
single	JJ	B-DOS
dose	NN	B-UNIT
of	IN	O
greater	JJR	O
than	IN	O
40	CD	B-DOS
mg	NN	B-UNIT
,	,	O
or	CC	O
a	DT	O
total	JJ	O
daily	JJ	B-FREQ
dose	NN	O
of	IN	O
greater	JJR	O
than	IN	O
80	CD	B-DOS
mg	NN	B-UNIT
,	,	O
are	VBP	O
only	RB	O
for	IN	O
use	NN	O
in	IN	O
patients	NNS	B-WHO
in	IN	I-WHO
whom	WP	I-WHO
tolerance	NN	I-WHO
to	TO	I-WHO
an	DT	I-WHO
opioid	NN	I-WHO
of	IN	I-WHO
comparable	JJ	I-WHO
potency	NN	I-WHO
has	VBZ	I-WHO
been	VBN	I-WHO
established	VBN	O-WHO
.	.	O

The	DT	O
usual	JJ	O
IV	NNP	O
dose	NN	O
is	VBZ	O
16	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
m²	NN	O
.	.	O

The	DT	O
usual	JJ	O
starting	VBG	O
dose	NN	O
of	IN	O
Diaβeta	NNP	O
as	IN	O
initial	JJ	O
therapy	NN	O
is	VBZ	O
2.5	CD	B-DOS
to	TO	O
5	CD	B-DOS
mg	NNS	B-UNIT
daily	RB	B-FREQ
,	,	O
administered	VBN	O
with	IN	O
breakfast	NN	O
or	CC	O
the	DT	O
first	JJ	O
main	JJ	O
meal	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
TORISEL	NNP	O
for	IN	O
advanced	JJ	O
renal	JJ	O
cell	NN	O
carcinoma	NN	O
is	VBZ	O
25	CD	B-DOS
mg	NN	B-UNIT
infused	VBN	O
over	IN	O
a	DT	O
30	CD	O
–	NN	O
60	CD	O
minute	NN	O
period	NN	O
once	IN	B-FREQ
a	DT	I-FREQ
week	NN	O-FREQ
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
of	IN	O
Orenitram	NNP	O
is	VBZ	O
0.25	CD	B-DOS
mg	JJ	B-UNIT
twice	RB	B-FREQ
daily	RB	O-FREQ
(	(	O
BID	NNP	O
)	)	O
with	IN	O
food	NN	O
,	,	O
taken	VBN	O
approximately	RB	O
12	CD	O
hours	NNS	O
apart	RB	O
or	CC	O
0.125	CD	B-DOS
mg	NNS	B-UNIT
three	CD	B-FREQ
times	NNS	I-FREQ
daily	RB	O-FREQ
(	(	O
TID	NNP	O
)	)	O
with	IN	O
food	NN	O
,	,	O
taken	VBN	O
approximately	RB	O
8	CD	O
hours	NNS	O
apart	RB	O
.	.	O

The	DT	O
recommended	JJ	O
regimen	NN	O
is	VBZ	O
a	DT	O
5	CD	B-DOS
mg	NN	B-UNIT
infusion	NN	O
once	RB	B-FREQ
a	DT	I-FREQ
year	NN	O-FREQ
given	VBN	O
intravenously	RB	O
over	IN	O
no	DT	O
less	JJR	O
than	IN	O
15	CD	O
minutes	NNS	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
VIVITROL	NNP	O
is	VBZ	O
380	CD	B-DOS
mg	NN	B-UNIT
delivered	VBD	O
intramuscularly	RB	O
every	DT	B-FREQ
4	CD	I-FREQ
weeks	NNS	O-FREQ
or	CC	O
once	RB	B-FREQ
a	DT	I-FREQ
month	NN	O-FREQ
.	.	O

PULMICORT	NNP	O
FLEXHALER	NNP	O
(	(	O
budesonide	JJ	O
inhalation	NN	O
powder	NN	O
)	)	O
should	MD	O
be	VB	O
administered	VBN	O
twice	RB	B-FREQ
daily	RB	O-FREQ
by	IN	O
the	DT	O
orally	RB	O
inhaled	VBN	O
route	NN	O
only	RB	O
.	.	O

A	DT	O
thin	JJ	O
film	NN	O
is	VBZ	O
applied	VBN	O
2	CD	B-FREQ
to	TO	O
4	CD	B-FREQ
times	NNS	I-FREQ
daily	RB	O-FREQ
to	TO	O
the	DT	O
affected	JJ	O
area	NN	O
.	.	O

The	DT	O
recommended	JJ	O
target	NN	O
dosage	NN	O
for	IN	O
VIIBRYD	NNP	O
is	VBZ	O
20	CD	B-DOS
mg	NN	B-UNIT
to	TO	O
40	CD	B-DOS
mg	NNS	B-UNIT
orally	RB	O
once	RB	B-FREQ
daily	JJ	O-FREQ
with	IN	O
food	NN	O
.	.	O

Initial	JJ	O
dosage	NN	O
range	NN	O
for	IN	O
adults	NNS	B-WHO
is	VBZ	O
100	CD	B-DOS
to	TO	O
200	CD	B-DOS
mL	NNS	B-UNIT
and	CC	O
for	IN	O
children	NNS	B-WHO
2.5	CD	B-DOS
to	TO	O
5	CD	B-DOS
mL	NNS	B-UNIT
per	IN	O
kilogram	NN	O
body	NN	O
weight	NN	O
.	.	O

The	DT	O
recommended	JJ	O
course	NN	O
of	IN	O
therapy	NN	O
for	IN	O
PROVENGE	NNP	O
is	VBZ	O
3	CD	B-DOS
complete	JJ	B-UNIT
doses	NNS	O-UNIT
,	,	O
given	VBN	O
at	IN	O
approximately	RB	O
2	CD	O
-	:	O
week	NN	O
intervals	NNS	O
.	.	O

The	DT	O
dosage	NN	O
range	NN	O
of	IN	O
LIPTRUZET	NNP	O
is	VBZ	O
10	CD	B-DOS
/	JJ	O
10	CD	O
/	JJ	O
18	CD	B-DOS
mg	JJ	B-UNIT
/	NNP	B-FREQ
day	NN	O-FREQ
to	TO	O
10	CD	B-DOS
/	NNS	O
80	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	B-FREQ
day	NN	O-FREQ
.	.	O

Apply	VB	O
the	DT	O
entire	JJ	O
contents	NNS	O
of	IN	O
the	DT	O
84	CD	O
-	:	O
gram	NN	O
package	NN	O
of	IN	O
SERPACWA	NNP	O
evenly	RB	O
to	TO	O
the	DT	O
areas	NNS	O
of	IN	O
the	DT	O
skin	NN	O
(	(	O
as	IN	O
outlined	VBN	O
in	IN	O
Instructions	NNP	O
for	IN	O
Use	NNP	O
for	IN	O
Military	NNP	O
Personnel	NNP	O
below	IN	O
)	)	O
prior	RB	O
to	TO	O
donning	VBG	O
MOPP	NNP	O
gear	NN	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
range	NN	O
for	IN	O
Sotret	NNP	O
(	(	O
isotret	JJ	O
(	(	O
isotret	JJ	O
(	(	O
isotretinoin	JJ	O
capsules	NNS	O
)	)	O
inoin	VBP	O
capsules	NNS	O
)	)	O
inoin	VBP	O
capsules	NNS	O
)	)	O
is	VBZ	O
0.5	CD	B-DOS
to	TO	O
1	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
kg	JJ	O
/	NNP	B-FREQ
day	NN	O-FREQ
given	VBN	O
in	IN	O
two	CD	B-DOS
divided	JJ	B-UNIT
doses	NNS	O-UNIT
with	IN	O
food	NN	O
for	IN	O
15	CD	B-DUR
to	TO	O
20	CD	B-DUR
weeks	NNS	O-DUR
.	.	O

The	DT	O
usual	JJ	O
adult	NN	B-WHO
dose	NN	O
is	VBZ	O
two	CD	B-DOS
capsules	NNS	B-UNIT
every	DT	B-FREQ
4	CD	I-FREQ
hours	NNS	O-FREQ
as	IN	O
needed	VBN	O
for	IN	O
pain	NN	O
.	.	O

FLOMAX	NNP	O
capsules	VBZ	O
0.4	CD	B-DOS
mg	NN	B-UNIT
once	RB	B-FREQ
daily	JJ	O-FREQ
is	VBZ	O
recommended	VBN	O
as	IN	O
the	DT	O
dose	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
the	DT	O
signs	NNS	O
and	CC	O
symptoms	NNS	O
of	IN	O
BPH	NNP	O
.	.	O

The	DT	O
initial	JJ	O
dosage	NN	O
is	VBZ	O
0.2	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
kg	VBZ	O
minoxidil	NN	O
as	IN	O
a	DT	O
single	JJ	B-DOS
daily	JJ	B-FREQ
dose	NN	B-UNIT
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
romidepsin	NN	O
is	VBZ	O
14	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
m2	NN	O
administered	VBD	O
intravenously	RB	O
over	IN	O
a	DT	O
4	CD	O
-	:	O
hour	NN	O
period	NN	O
on	IN	O
days	NNS	O
1	CD	O
,	,	O
8	CD	O
,	,	O
and	CC	O
15	CD	O
of	IN	O
a	DT	O
28	CD	O
-	:	O
day	NN	O
cycle	NN	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
OLYSIO	NNP	O
is	VBZ	O
one	CD	B-DOS
150	CD	O-DOS
mg	NN	B-UNIT
capsule	NN	O-UNIT
taken	VBN	O
orally	RB	O
once	RB	B-FREQ
daily	JJ	O-FREQ
with	IN	O
food	NN	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
range	NN	O
for	IN	O
Zenatane	NNP	O
is	VBZ	O
0.5	CD	B-DOS
to	TO	O
1	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
kg	JJ	O
/	NNP	B-FREQ
day	NN	O-FREQ
given	VBN	O
in	IN	O
two	CD	B-DOS
divided	JJ	B-UNIT
doses	NNS	O-UNIT
with	IN	O
food	NN	O
for	IN	O
15	CD	B-DUR
to	TO	O
20	CD	B-DUR
weeks	NNS	O-DUR
.	.	O

For	IN	O
the	DT	O
treatment	NN	O
of	IN	O
HIV	NNP	O
-	:	O
1	CD	B-DOS
or	CC	O
chronic	JJ	O
hepatitis	NN	O
B	NNP	O
:	:	O
The	DT	O
dose	NN	O
is	VBZ	O
one	CD	B-DOS
300	CD	O-DOS
mg	NN	B-UNIT
VIREAD	NNP	I-UNIT
tablet	NN	O-UNIT
once	RB	B-FREQ
daily	RB	O-FREQ
taken	VBN	O
orally	RB	O
,	,	O
without	IN	O
regard	NN	O
to	TO	O
food	NN	O
.	.	O

It	PRP	O
is	VBZ	O
recommended	VBN	O
that	IN	O
the	DT	O
patient	NN	O
be	VB	O
started	VBN	O
on	IN	O
200	CD	B-DOS
mg	NNS	B-UNIT
,	,	O
two	CD	B-FREQ
or	CC	O
three	CD	B-FREQ
times	NNS	I-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
RELISTOR	NNP	O
is	VBZ	O
12	CD	B-DOS
mg	NN	B-UNIT
subcutaneously	RB	O
once	RB	B-FREQ
daily	JJ	O-FREQ
.	.	O

The	DT	O
usual	JJ	O
dosage	NN	O
range	NN	O
is	VBZ	O
5	CD	B-DOS
to	TO	O
40	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	B-FREQ
day	NN	O-FREQ
.	.	O

The	DT	O
suggested	JJ	O
total	JJ	O
daily	JJ	B-FREQ
dose	NN	O
is	VBZ	O
8	CD	B-DOS
to	TO	O
30	CD	B-DOS
mg	NNS	B-UNIT
per	IN	O
kg	NN	O
in	IN	O
divided	JJ	O
doses	NNS	O
.	.	O

Hodgkin	NNP	O
's	POS	O
disease	NN	O
-	:	O
0.25	CD	B-DOS
to	TO	O
0.5	CD	B-DOS
units	NNS	B-UNIT
/	JJ	O
kg	NN	O
(	(	O
10	CD	B-DOS
to	TO	O
20	CD	B-DOS
units	NNS	B-UNIT
/	NNP	O
m²	NN	O
)	)	O
given	VBN	O
intravenously	RB	O
,	,	O
intramuscularly	RB	O
,	,	O
or	CC	O
subcutaneously	RB	O
weekly	JJ	B-FREQ
or	CC	O
twice	JJ	B-FREQ
weekly	RB	O-FREQ
.	.	O

The	DT	O
maximum	JJ	O
dose	NN	O
is	VBZ	O
1.2	CD	B-DOS
mg	JJ	B-UNIT
per	IN	B-FREQ
day	NN	O-FREQ
.	.	O

The	DT	O
maximum	JJ	O
dosing	NN	O
frequency	NN	O
is	VBZ	O
one	CD	B-DOS
STAXYN	NNP	B-UNIT
tablet	NN	O-UNIT
per	IN	B-FREQ
day	NN	O-FREQ
.	.	O

The	DT	O
usual	JJ	O
recommended	VBD	O
starting	VBG	O
dose	NN	O
is	VBZ	O
20	CD	B-DOS
,	,	O
40	CD	B-DOS
,	,	O
or	CC	O
60	CD	B-DOS
mg	NN	B-UNIT
once	RB	B-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
given	VBN	O
in	IN	O
the	DT	O
evening	NN	O
at	IN	O
bedtime	NN	O
.	.	O

The	DT	O
usual	JJ	O
recommended	JJ	O
dosage	NN	O
for	IN	O
systemic	JJ	O
and	CC	O
urinary	JJ	O
tract	NN	O
infections	NNS	O
for	IN	O
adults	NNS	B-WHO
is	VBZ	O
3.1	CD	B-DOS
grams	NNS	B-UNIT
of	IN	O
TIMENTIN	NNP	O
(	(	O
3	CD	B-DOS
grams	NNS	B-UNIT
ticarcillin	NN	O
and	CC	O
100	CD	B-DOS
mg	NN	B-UNIT
clavulanic	JJ	O
acid	NN	O
)	)	O
given	VBN	O
every	DT	B-FREQ
4	CD	O-FREQ
to	TO	O
6	CD	B-FREQ
hours	NNS	O-FREQ
.	.	O

The	DT	O
initial	JJ	O
dosage	NN	O
of	IN	O
PEDIAPRED	NNP	O
(	(	O
prednisolone	JJ	O
sodium	NN	O
)	)	O
may	MD	O
vary	VB	O
from	IN	O
5	CD	B-DOS
mL	NNS	B-UNIT
to	TO	O
60	CD	B-DOS
mL	NN	B-UNIT
(	(	O
5	CD	B-DOS
to	TO	O
60	CD	B-DOS
mg	NN	B-UNIT
prednisolone	NN	O
base	NN	O
)	)	O
per	IN	B-FREQ
day	NN	O-FREQ
depending	VBG	O
on	IN	O
the	DT	O
specific	JJ	O
disease	NN	O
entity	NN	O
being	VBG	O
treated	VBN	O
.	.	O

SIMCOR	NNP	O
should	MD	O
be	VB	O
taken	VBN	O
as	IN	O
a	DT	O
single	JJ	B-DOS
daily	JJ	B-FREQ
dose	NN	B-UNIT
at	IN	O
bedtime	NN	O
,	,	O
with	IN	O
a	DT	O
low	JJ	O
fat	JJ	O
snack	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
Fortical	NNP	O
nasal	NN	O
spray	NN	O
is	VBZ	O
1	CD	B-DOS
spray	NN	B-UNIT
(	(	O
200	CD	B-DOS
International	NNP	B-UNIT
Units	NNP	O-UNIT
)	)	O
per	IN	B-FREQ
day	NN	O-FREQ
intranasally	RB	O
,	,	O
alternating	VBG	O
nostrils	JJ	O
daily	JJ	B-FREQ
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
10	CD	B-DOS
to	TO	O
20	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
kg	JJ	O
daily	JJ	B-FREQ
intravenously	RB	O
for	IN	O
8	CD	B-DUR
to	TO	O
14	CD	B-DUR
days	NNS	O-DUR
.	.	O

The	DT	O
usual	JJ	O
dosage	NN	O
in	IN	O
adults	NNS	B-WHO
for	IN	O
maintenance	NN	O
of	IN	O
remission	NN	O
is	VBZ	O
1	CD	B-DOS
g	JJ	B-UNIT
/	NNP	B-FREQ
day	NN	O-FREQ
in	IN	O
two	CD	B-DOS
divided	JJ	B-UNIT
doses	NNS	O-UNIT
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
range	NN	O
for	IN	O
FETZIMA	NNP	O
is	VBZ	O
40	CD	B-DOS
mg	NN	B-UNIT
to	TO	O
120	CD	B-DOS
mg	NNS	B-UNIT
once	RB	B-FREQ
daily	RB	O-FREQ
,	,	O
with	IN	O
or	CC	O
without	IN	O
food	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
2	CD	B-DOS
to	TO	O
4	CD	B-DOS
g	NNS	B-UNIT
intravaginally	RB	O
per	IN	B-FREQ
day	NN	O-FREQ
,	,	O
adjusted	VBN	O
to	TO	O
the	DT	O
lowest	JJS	O
amount	NN	O
that	WDT	O
controls	VBZ	O
symptoms	NNS	O
.	.	O

The	DT	O
usual	JJ	O
starting	VBG	O
dose	NN	O
of	IN	O
COZAAR	NNP	O
is	VBZ	O
50	CD	B-DOS
mg	NN	B-UNIT
once	RB	B-FREQ
daily	RB	O-FREQ
.	.	O

Apply	RB	O
1	CD	B-DOS
–	JJ	O
4	CD	B-DOS
pumps	NNS	B-UNIT
up	RB	O
to	TO	O
four	CD	B-FREQ
times	NNS	I-FREQ
per	IN	I-FREQ
day	NN	O-FREQ
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
complicated	VBN	O
skin	NN	O
and	CC	O
skin	NN	O
structure	NN	O
infections	NNS	O
is	VBZ	O
7.5	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
kg	NN	O
q12h	NN	O
.	.	O

The	DT	O
dosage	NN	O
of	IN	O
FARESTON	NNP	O
is	VBZ	O
60	CD	B-DOS
mg	NN	B-UNIT
,	,	O
once	RB	B-FREQ
daily	JJ	O-FREQ
,	,	O
orally	RB	O
.	.	O

For	IN	O
the	DT	O
treatment	NN	O
of	IN	O
chronic	JJ	O
eczematous	JJ	O
external	JJ	O
otitis	NN	O
,	,	O
using	VBG	O
the	DT	O
supplied	JJ	O
ear	JJ	O
-	:	O
dropper	NN	O
,	,	O
apply	VB	O
5	CD	B-DOS
drops	NNS	B-UNIT
of	IN	O
DermOtic®	NNP	O
Oil	NNP	O
(	(	O
fluocinolone	NN	O
acetonide	RB	O
oil	NN	O
ear	JJ	O
drops	NN	O
)	)	O
into	IN	O
the	DT	O
affected	JJ	O
ear	NN	O
.	.	O

The	DT	O
usual	JJ	O
adult	NN	B-WHO
dosage	NN	O
for	IN	O
tablets	NNS	O
is	VBZ	O
15	CD	B-DOS
mg	NN	B-UNIT
to	TO	O
60	CD	B-DOS
mg	NNS	B-UNIT
repeated	VBD	O
up	RB	O
to	TO	O
every	DT	B-FREQ
four	CD	I-FREQ
hours	NNS	O-FREQ
as	IN	O
needed	VBN	O
for	IN	O
pain	NN	O
.	.	O

This	DT	O
dose	NN	O
should	MD	O
be	VB	O
administered	VBN	O
5	CD	B-FREQ
to	TO	O
6	CD	B-FREQ
times	NNS	I-FREQ
daily	RB	O-FREQ
(	(	O
5	CD	B-DOS
to	TO	O
6	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
kg	JJ	O
daily	JJ	O
)	)	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
of	IN	O
ETHYOL	NNP	O
(	(	O
amifostine	NN	O
)	)	O
is	VBZ	O
910	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
m2	NN	O
administered	VBD	O
once	RB	B-FREQ
daily	JJ	O-FREQ
as	IN	O
a	DT	O
15	CD	B-DOS
-	:	O
minute	NN	O
i.v	NN	O
.	.	O

The	DT	O
recommended	JJ	O
dosages	NNS	O
of	IN	O
ELLENCE	NNP	O
are	VBP	O
as	IN	O
follows	VBZ	O
:	:	O
The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
ELLENCE	NNP	O
is	VBZ	O
100	CD	B-DOS
to	TO	O
120	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
m²	NN	O
.	.	O

For	IN	O
management	NN	O
of	IN	O
bronchial	JJ	O
asthma	NN	O
in	IN	O
adults	NNS	B-WHO
and	CC	I-WHO
pediatric	JJ	I-WHO
patients	NNS	O-WHO
(	(	O
two	CD	O
years	NNS	O
of	IN	O
age	NN	O
and	CC	O
over	IN	O
)	)	O
,	,	O
the	DT	O
usual	JJ	O
starting	NN	O
dosage	NN	O
is	VBZ	O
the	DT	O
contents	NNS	O
of	IN	O
one	CD	B-DOS
ampule	NN	B-UNIT
administered	VBN	O
by	IN	O
nebulization	NN	O
four	CD	B-FREQ
times	NNS	I-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
at	IN	O
regular	JJ	O
intervals	NNS	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
of	IN	O
Corlanor	NNP	O
is	VBZ	O
5	CD	B-DOS
mg	JJ	B-UNIT
twice	RB	B-FREQ
daily	RB	O-FREQ
with	IN	O
meals	NNS	O
.	.	O

The	DT	O
recommended	JJ	O
initial	JJ	O
dose	NN	O
of	IN	O
CALCIJEX®	NNP	O
is	VBZ	O
0.5	CD	B-DOS
mcg	NN	B-UNIT
(	(	O
0.01	CD	B-DOS
mcg	NN	B-UNIT
/	NNP	O
kg	NN	O
)	)	O
administered	VBD	O
three	CD	B-FREQ
times	NNS	I-FREQ
weekly	RB	O-FREQ
,	,	O
every	DT	B-FREQ
other	JJ	I-FREQ
day	NN	O-FREQ
.	.	O

A	DT	O
dose	NN	O
of	IN	O
1	CD	B-DOS
capsule	NN	B-UNIT
four	CD	B-FREQ
times	NNS	I-FREQ
daily	RB	O-FREQ
is	VBZ	O
suggested	VBN	O
.	.	O

The	DT	O
range	NN	O
of	IN	O
initial	JJ	O
doses	NNS	O
is	VBZ	O
0.11	CD	B-DOS
to	TO	O
1.6	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
kg	JJ	O
/	NNP	B-FREQ
day	NN	O-FREQ
in	IN	O
three	CD	B-DOS
or	CC	O
four	CD	B-DOS
divided	VBN	B-UNIT
doses	NNS	O-UNIT
(	(	O
3.2	CD	B-DOS
to	TO	O
48	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
m²bsa	JJ	O
/	NNP	B-FREQ
day	NN	O-FREQ
)	)	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
NATRECOR®	NNP	O
is	VBZ	O
an	DT	O
IV	NNP	O
bolus	NN	O
of	IN	O
2	CD	B-DOS
mcg	NNS	B-UNIT
/	JJ	O
kg	NN	O
followed	VBN	O
by	IN	O
a	DT	O
continuous	JJ	O
infusion	NN	O
of	IN	O
0.01	CD	B-DOS
mcg	NNS	B-UNIT
/	JJ	O
kg	FW	O
/	JJ	O
min	NN	O
.	.	O

The	DT	O
usual	JJ	O
parenteral	NN	O
dose	NN	O
is	VBZ	O
25	CD	B-DOS
to	TO	O
50	CD	B-DOS
mg	NNS	B-UNIT
given	VBN	O
subcutaneously	RB	O
or	CC	O
intramuscularly	RB	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
and	CC	O
target	NN	O
dose	NN	O
for	IN	O
ABILIFY	NNP	O
is	VBZ	O
10	CD	B-DOS
or	CC	O
15	CD	B-DOS
mg	JJ	B-UNIT
/	NNP	B-FREQ
day	NN	O-FREQ
administered	VBD	O
on	IN	O
a	DT	O
once	RB	B-FREQ
-	:	I-FREQ
a	DT	I-FREQ
-	:	I-FREQ
day	NN	O-FREQ
schedule	NN	O
without	IN	O
regard	NN	O
to	TO	O
meals	NNS	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
HARVONI	NNP	O
is	VBZ	O
one	CD	B-DOS
tablet	NN	B-UNIT
taken	VBN	O
orally	RB	O
once	RB	B-FREQ
daily	JJ	O-FREQ
with	IN	O
or	CC	O
without	IN	O
food	NN	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
ODEFSEY	NNP	O
is	VBZ	O
one	CD	B-DOS
tablet	NN	B-UNIT
taken	VBN	O
orally	RB	O
once	RB	B-FREQ
daily	JJ	O-FREQ
with	IN	O
a	DT	O
meal	NN	O
in	IN	O
the	DT	O
following	JJ	O
patient	JJ	O
population	NN	O
:	:	O
adults	NNS	B-WHO
and	CC	I-WHO
in	IN	I-WHO
pediatric	JJ	I-WHO
patients	NNS	I-WHO
12	CD	I-WHO
years	NNS	I-WHO
of	IN	I-WHO
age	NN	I-WHO
and	CC	I-WHO
older	JJR	I-WHO
with	IN	I-WHO
body	NN	I-WHO
weight	NN	I-WHO
greater	JJR	I-WHO
than	IN	O-WHO
or	CC	O
equal	JJ	O
to	TO	O
35	CD	O
kg	NNS	O
and	CC	O
a	DT	O
creatinine	JJ	O
clearance	NN	O
greater	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
30	CD	B-DOS
mL	NNS	B-UNIT
per	IN	O
minute	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
REBIF	NNP	O
is	VBZ	O
either	RB	O
22	CD	B-DOS
mcg	NN	B-UNIT
or	CC	O
44	CD	B-DOS
mcg	NNS	B-UNIT
injected	VBD	O
subcutaneously	RB	O
three	CD	B-FREQ
times	NNS	I-FREQ
per	IN	I-FREQ
week	NN	O-FREQ
.	.	O

The	DT	O
usual	JJ	O
adult	NN	B-WHO
dosage	NN	O
is	VBZ	O
1	CD	B-DOS
or	CC	O
2	CD	B-DOS
mg	NN	B-UNIT
2	CD	B-FREQ
times	NNS	I-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
.	.	O

Instill	NNP	O
one	CD	B-DOS
drop	NN	B-UNIT
in	IN	O
the	DT	O
affected	JJ	O
eye	NN	O
(	(	O
s	JJ	O
)	)	O
3	CD	B-FREQ
times	NNS	I-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
,	,	O
four	CD	O
to	TO	O
twelve	VB	O
hours	NNS	O
apart	RB	O
for	IN	O
7	CD	B-DUR
days	NNS	O-DUR
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
ZYTIGA	NNP	O
is	VBZ	O
1000	CD	B-DOS
mg	NN	B-UNIT
(	(	O
four	CD	B-DOS
250	CD	O-DOS
mg	NNS	B-UNIT
tablets	NNS	O-UNIT
)	)	O
administered	VBD	O
orally	RB	O
once	RB	B-FREQ
daily	JJ	O-FREQ
in	IN	O
combination	NN	O
with	IN	O
prednisone	NN	O
5	CD	B-DOS
mg	NN	B-UNIT
administered	VBN	O
orally	RB	O
twice	JJ	B-FREQ
daily	NN	O-FREQ
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
one	CD	B-DOS
drop	NN	B-UNIT
of	IN	O
OptiPranolol	NNP	O
(	(	O
metipranolol	JJ	O
ophthalmic	JJ	O
solution	NN	O
)	)	O
Ophthalmic	NNP	O
Solution	NNP	O
in	IN	O
the	DT	O
affected	JJ	O
eye	NN	O
(	(	O
s	JJ	O
)	)	O
twice	RB	B-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
.	.	O

Apply	VB	O
the	DT	O
0.1	CD	O
%	NN	O
HALOG	NNP	O
(	(	O
Halcinonide	NNP	O
Cream	NNP	O
,	,	O
USP	NNP	O
)	)	O
to	TO	O
the	DT	O
affected	JJ	O
area	NN	O
two	CD	B-FREQ
to	TO	O
three	CD	B-FREQ
times	NNS	I-FREQ
daily	RB	O-FREQ
.	.	O

The	DT	O
recommended	JJ	O
initiating	NN	O
dose	NN	O
of	IN	O
TRULICITY	NNP	O
is	VBZ	O
0.75	CD	B-DOS
mg	NN	B-UNIT
once	RB	B-FREQ
weekly	JJ	O-FREQ
.	.	O

Adults	NNS	O
:	:	O
1	CD	B-DOS
or	CC	O
2	CD	B-DOS
capsules	NNS	B-UNIT
twice	RB	B-FREQ
daily	RB	O-FREQ
.	.	O

Take	VB	O
10	CD	B-DOS
mg	NNS	B-UNIT
to	TO	O
15	CD	B-DOS
mg	NNS	B-UNIT
dose	NN	O
of	IN	O
METOZOLV	NNP	O
ODT	NNP	O
up	RB	O
to	TO	O
four	CD	B-FREQ
times	NNS	I-FREQ
daily	RB	O-FREQ
(	(	O
e.g	NN	O
.	.	O
,	,	O
at	IN	O
least	JJS	O
30	CD	O
minutes	NNS	O
before	IN	O
each	DT	O
meal	NN	O
and	CC	O
at	IN	O
bedtime	NN	O
)	)	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
of	IN	O
atorvastatin	NN	O
is	VBZ	O
10	CD	B-DOS
or	CC	O
20	CD	B-DOS
mg	NNS	B-UNIT
once	RB	B-FREQ
daily	RB	O-FREQ
.	.	O

The	DT	O
recommended	VBN	O
CYSTAGON®	NNP	O
(	(	O
cysteamine	JJ	O
bitartrate	NN	O
)	)	O
maintenance	NN	O
dose	NN	O
for	IN	O
children	NNS	O
up	RB	O
to	TO	O
age	NN	O
12	CD	O
years	NNS	O
is	VBZ	O
1.3	CD	B-DOS
grams	NNS	B-UNIT
/	VBP	O
m2	JJ	O
/	NNP	B-FREQ
day	NN	O-FREQ
of	IN	O
the	DT	O
free	JJ	O
base	NN	O
,	,	O
given	VBN	O
in	IN	O
four	CD	B-DOS
divided	JJ	B-UNIT
doses	NNS	O-UNIT
.	.	O

For	IN	O
most	JJS	B-WHO
patients	NNS	O-WHO
,	,	O
the	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
FLEXERIL	NNP	O
is	VBZ	O
5	CD	B-DOS
mg	NN	B-UNIT
three	CD	B-FREQ
times	NNS	I-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
.	.	O

For	IN	O
the	DT	O
short	JJ	O
-	:	O
term	NN	O
(	(	O
generally	RB	O
less	JJR	O
than	IN	O
10	CD	O
days	NNS	O
)	)	O
management	NN	O
of	IN	O
acute	NN	O
pain	NN	O
,	,	O
the	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
REPREXAIN™	NNP	O
is	VBZ	O
one	CD	B-DOS
tablet	NN	B-UNIT
every	DT	O
4	CD	B-FREQ
to	TO	O
6	CD	B-FREQ
hours	NNS	O-FREQ
,	,	O
as	IN	O
necessary	JJ	O
.	.	O

For	IN	O
peripheral	JJ	O
intravenous	JJ	O
infusion	NN	O
,	,	O
1	CD	B-DOS
to	TO	O
1.5	CD	B-DOS
g	NNS	B-UNIT
/	JJ	O
kg	JJ	O
/	NNP	B-FREQ
day	NN	O-FREQ
of	IN	O
total	JJ	O
amino	NN	O
acids	NNS	O
will	MD	O
reduce	VB	O
protein	JJ	O
catabolism	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
Pamidronate	NNP	O
disodium	NN	O
for	IN	O
Injection	NNP	O
USP	NNP	O
in	IN	O
severe	JJ	O
hypercalcemia	NN	O
(	(	O
corrected	VBN	O
serum	NN	O
calcium*	NN	O
>	VBD	O
13.5	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
dL	NN	O
)	)	O
is	VBZ	O
90	CD	B-DOS
mg	NN	B-UNIT
given	VBN	O
as	IN	O
a	DT	O
SINGLE	NNP	B-DOS
-	:	O
DOSE	NNP	B-UNIT
,	,	O
intravenous	JJ	O
infusion	NN	O
over	IN	O
2	CD	O
to	TO	O
24	CD	O
hours	NNS	O
.	.	O

The	DT	O
usual	JJ	O
dosage	NN	O
of	IN	O
PCE	NNP	O
tablets	NNS	O
are	VBP	O
one	CD	B-DOS
333	CD	O-DOS
mg	NN	B-UNIT
tablet	NN	O-UNIT
every	DT	B-FREQ
8	CD	I-FREQ
hours	NNS	O-FREQ
or	CC	O
one	CD	B-DOS
500	CD	O-DOS
mg	NN	B-UNIT
tablet	NN	O-UNIT
every	DT	B-FREQ
12	CD	I-FREQ
hours	NNS	O-FREQ
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
AMERGE	NNP	O
is	VBZ	O
1	CD	B-DOS
mg	NN	B-UNIT
or	CC	O
2.5	CD	B-DOS
mg	NN	B-UNIT
.	.	O

Generally	RB	O
,	,	O
it	PRP	O
is	VBZ	O
recommended	VBN	O
that	IN	O
Dritho	NNP	O
-	:	O
Scalp	NN	O
be	VB	O
applied	VBN	O
once	RB	B-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
or	CC	O
as	IN	O
directed	VBN	O
by	IN	O
a	DT	O
physician	NN	O
.	.	O

1	CD	B-DOS
or	CC	O
2	CD	B-DOS
capsules	NNS	B-UNIT
every	DT	B-FREQ
4	CD	I-FREQ
hours	NNS	O-FREQ
as	IN	O
needed	VBN	O
.	.	O

The	DT	O
suggested	JJ	O
starting	NN	O
dose	NN	O
is	VBZ	O
between	IN	O
0.2	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	B-FREQ
hr*	NN	O-FREQ
,	,	O
and	CC	O
0.4	CD	B-DOS
mg	NN	B-UNIT
/	NNP	B-FREQ
hr*	NN	O-FREQ
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
for	IN	O
REMERONSolTab®	NNP	O
(	(	O
mirtazapine	NN	O
)	)	O
Orally	RB	O
Disintegrating	VBG	O
Tablets	NNP	O
is	VBZ	O
15	CD	B-DOS
mg	JJ	B-UNIT
/	NNP	B-FREQ
day	NN	O-FREQ
,	,	O
administered	VBN	O
in	IN	O
a	DT	O
single	JJ	B-DOS
dose	NN	B-UNIT
,	,	O
preferably	RB	O
in	IN	O
the	DT	O
evening	NN	O
prior	RB	O
to	TO	O
sleep	VB	O
.	.	O

Metastatic	JJ	O
Testicular	NNP	O
Tumors	NNPS	O
-	:	O
The	DT	O
usual	JJ	O
cisplatin	NN	O
(	(	O
cisplatin	JJ	O
injection	NN	O
)	)	O
dose	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
testicular	JJ	O
cancer	NN	O
in	IN	O
combination	NN	O
with	IN	O
other	JJ	O
approved	VBN	O
chemotherapeutic	JJ	O
agents	NNS	O
is	VBZ	O
20	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
m2	NN	O
IV	NNP	O
daily	RB	B-FREQ
for	IN	O
5	CD	B-DUR
days	NNS	O-DUR
per	IN	O
cycle	NN	O
.	.	O

The	DT	O
recommended	VBN	O
adult	NN	B-WHO
dose	NN	O
of	IN	O
Oforta™	NNP	O
(	(	O
fludarabine	JJ	O
phosphate	NN	O
tablets	NNS	O
)	)	O
is	VBZ	O
40	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
m	NN	O
administered	VBN	O
by	IN	O
mouth	JJ	O
daily	JJ	B-FREQ
for	IN	O
five	CD	B-DUR
consecutive	JJ	I-DUR
days	NNS	O-DUR
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
25	CD	B-DOS
to	TO	O
40	CD	B-DOS
IU	NNP	B-UNIT
of	IN	O
IDELVION	NNP	O
per	IN	O
kg	NN	O
body	NN	O
weight	VBD	O
every	DT	B-FREQ
7	CD	I-FREQ
days	NNS	O-FREQ
,	,	O
or	CC	O
50	CD	B-DOS
to	TO	O
75	CD	B-DOS
IU	NNP	B-UNIT
of	IN	O
IDELVION	NNP	O
per	IN	O
kg	NN	O
every	DT	B-FREQ
14	CD	I-FREQ
days	NNS	O-FREQ
.	.	O

The	DT	O
usual	JJ	O
adult	NN	B-WHO
dosage	NN	O
is	VBZ	O
two	CD	B-DOS
(	(	O
2	CD	B-DOS
)	)	O
TREZIX™	NNP	B-DOS
capsules	NNS	B-UNIT
orally	RB	O
every	DT	B-FREQ
four	CD	O-FREQ
(	(	O
4	CD	B-FREQ
)	)	O
hours	NNS	B-FREQ
,	,	O
as	IN	O
needed	VBN	O
.	.	O

The	DT	O
maximum	JJ	O
daily	JJ	B-FREQ
dosage	NN	O
should	MD	O
not	RB	O
exceed	VB	O
12	CD	B-DOS
grams	NNS	B-UNIT
.	.	O

The	DT	O
initial	JJ	O
intramuscular	JJ	O
dosage	NN	O
of	IN	O
triamcinolone	NN	O
diacetate	NN	O
injectable	JJ	O
suspension	NN	O
may	MD	O
vary	VB	O
from	IN	O
3	CD	B-DOS
to	TO	O
48	CD	B-DOS
mg	NNS	B-UNIT
per	IN	B-FREQ
day	NN	O-FREQ
depending	VBG	O
on	IN	O
the	DT	O
specific	JJ	O
disease	NN	O
entity	NN	O
being	VBG	O
treated	VBN	O
.	.	O

The	DT	O
usual	JJ	O
adult	NN	B-WHO
dosage	NN	O
is	VBZ	O
one	CD	B-DOS
tablespoonful	NN	B-UNIT
every	DT	B-FREQ
4	CD	O-FREQ
to	TO	O
6	CD	B-FREQ
hours	NNS	O-FREQ
as	IN	O
needed	VBN	O
for	IN	O
pain	NN	O
.	.	O

Usual	JJ	O
dose	NN	O
is	VBZ	O
5	CD	B-DOS
to	TO	O
60	CD	B-DOS
mg	NNS	B-UNIT
per	IN	B-FREQ
day	NN	O-FREQ
in	IN	O
divided	JJ	O
doses	NNS	O
,	,	O
depending	VBG	O
on	IN	O
the	DT	O
individual	JJ	O
patient	NN	O
response	NN	O
.	.	O

For	IN	O
intravenous	JJ	O
use	NN	O
,	,	O
Novolin	NNP	O
R	NNP	O
should	MD	O
be	VB	O
used	VBN	O
at	IN	O
concentrations	NNS	O
from	IN	O
0.05	CD	B-DOS
units	NNS	B-UNIT
/	RB	O
mL	VBP	O
to	TO	O
1	CD	B-DOS
unit	NN	B-UNIT
/	JJ	O
mL	NN	O
in	IN	O
infusion	NN	O
systems	NNS	O
using	VBG	O
polypropylene	JJ	O
infusion	NN	O
bags	NNS	O
.	.	O

The	DT	O
initial	JJ	O
dose	NN	O
is	VBZ	O
50	CD	B-DOS
to	TO	O
150	CD	B-DOS
mg	NNS	B-UNIT
per	IN	B-FREQ
day	NN	O-FREQ
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
INCIVEK	NNP	O
tablets	NNS	O
is	VBZ	O
1125	CD	B-DOS
mg	NN	B-UNIT
(	(	O
three	CD	B-DOS
375	CD	O-DOS
-	:	O
mg	NN	B-UNIT
tablets	NNS	O-UNIT
)	)	O
taken	VBN	O
orally	RB	O
twice	JJ	B-FREQ
daily	RB	O-FREQ
(	(	O
10	CD	O
-	:	O
14	CD	O
hours	NNS	O
apart	RB	O
)	)	O
with	IN	O
food	NN	O
(	(	O
not	RB	O
low	JJ	O
fat	NN	O
)	)	O
.	.	O

Treatment	NN	O
of	IN	O
Testicular	JJ	O
Tumors	NNS	O
:	:	O
In	IN	O
the	DT	O
treatment	NN	O
of	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
testicular	JJ	I-WHO
tumors	NNS	O-WHO
the	DT	O
recommended	JJ	O
daily	JJ	B-FREQ
dose	NN	O
of	IN	O
Mithracin	NNP	O
(	(	O
plicamycin	NN	O
)	)	O
is	VBZ	O
25	CD	B-DOS
to	TO	O
30	CD	B-DOS
mcg	NN	B-UNIT
(	(	O
0.025	CD	B-DOS
-	:	O
0.03	CD	B-DOS
mg	NN	B-UNIT
)	)	O
per	IN	O
kilogram	NN	O
of	IN	O
body	NN	O
weight	NN	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
is	VBZ	O
0.0625	CD	B-DOS
mg	NN	B-UNIT
(	(	O
0.25	CD	B-DOS
mL	NN	B-UNIT
)	)	O
subcutaneously	RB	O
every	DT	B-FREQ
other	JJ	I-FREQ
day	NN	O-FREQ
,	,	O
with	IN	O
dose	JJ	O
increases	NNS	O
over	IN	O
a	DT	O
six	CD	O
-	:	O
week	NN	O
period	NN	O
to	TO	O
the	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
0.25	CD	B-DOS
mg	NN	B-UNIT
(	(	O
1	CD	B-DOS
mL	NN	B-UNIT
)	)	O
every	DT	B-FREQ
other	JJ	I-FREQ
day	NN	O-FREQ
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
Feraheme	NNP	O
is	VBZ	O
an	DT	O
initial	JJ	O
510	CD	B-DOS
mg	NN	B-UNIT
dose	NN	O
followed	VBN	O
by	IN	O
a	DT	O
second	JJ	O
510	CD	B-DOS
mg	NN	B-UNIT
dose	VBD	O
3	CD	O
to	TO	O
8	CD	O
days	NNS	O
later	RB	O
.	.	O

The	DT	O
recommended	JJ	O
initial	JJ	O
dose	NN	O
is	VBZ	O
20	CD	B-DOS
mg	NN	B-FREQ
four	CD	I-FREQ
times	NNS	I-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
.	.	O

The	DT	O
initial	JJ	O
dosage	NN	O
of	IN	O
CORTEF	NNP	O
Tablets	NNP	O
may	MD	O
vary	VB	O
from	IN	O
20	CD	B-DOS
mg	NNS	B-UNIT
to	TO	O
240	CD	B-DOS
mg	NN	B-UNIT
of	IN	O
hydrocortisone	NN	O
per	IN	B-FREQ
day	NN	O-FREQ
depending	VBG	O
on	IN	O
the	DT	O
specific	JJ	O
disease	NN	O
entity	NN	O
being	VBG	O
treated	VBN	O
.	.	O

Apply	VB	O
a	DT	O
thin	JJ	O
film	NN	O
to	TO	O
affected	VBN	O
areas	NNS	O
with	IN	O
light	JJ	O
massaging	VBG	O
,	,	O
1	CD	B-FREQ
to	TO	O
3	CD	B-FREQ
times	NNS	I-FREQ
daily	RB	O-FREQ
,	,	O
or	CC	O
as	IN	O
directed	VBN	O
by	IN	O
a	DT	O
physician	NN	O
.	.	O

The	DT	O
dosage	NN	O
delivered	VBN	O
is	VBZ	O
0.5	CD	B-DOS
-	:	O
1	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
kg	NN	O
of	IN	O
edrophonium	NN	O
chloride	NN	O
and	CC	O
0.007	CD	B-DOS
-	:	O
0.014	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
kg	NN	O
of	IN	O
atropine	JJ	O
sulfate	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
doxorubicin	NN	O
HCl	NNP	O
is	VBZ	O
60	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
m	NN	O
administered	VBD	O
as	IN	O
an	DT	O
intravenous	JJ	O
bolus	NN	O
on	IN	O
day	NN	O
1	CD	O
of	IN	O
each	DT	O
21	CD	O
-	:	O
day	NN	O
treatment	NN	O
cycle	NN	O
,	,	O
in	IN	O
combination	NN	O
with	IN	O
cyclophosphamide	NN	O
,	,	O
for	IN	O
a	DT	O
total	NN	O
of	IN	O
four	CD	O
cycles	NNS	O
.	.	O

For	IN	O
adults	NNS	B-WHO
,	,	O
the	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
Asacol	NNP	O
is	VBZ	O
two	CD	B-DOS
400	CD	O-DOS
mg	NNS	B-UNIT
tablets	NNS	O-UNIT
to	TO	O
be	VB	O
taken	VBN	O
three	CD	B-FREQ
times	NNS	I-FREQ
daily	JJ	O-FREQ
with	IN	O
or	CC	O
without	IN	O
food	NN	O
(	(	O
total	JJ	O
daily	RB	B-FREQ
dose	NN	O
of	IN	O
2.4	CD	B-DOS
grams	NNS	B-UNIT
)	)	O
,	,	O
for	IN	O
a	DT	O
duration	NN	O
of	IN	O
6	CD	O
weeks	NNS	O
[	JJ	O
see	VBP	O
Clinical	JJ	O
Studies	NNP	O
]	NNP	O
.	.	O

Toenail	JJ	O
onychomycosis	NN	O
:	:	O
One	CD	B-DOS
250	CD	O-DOS
mg	NN	B-UNIT
tablet	NN	O-UNIT
once	RB	B-FREQ
daily	JJ	O-FREQ
for	IN	O
12	CD	B-DUR
weeks	NNS	O-DUR
.	.	O

For	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
moderate	JJ	I-WHO
to	TO	I-WHO
moderately	RB	I-WHO
severe	JJ	I-WHO
chronic	NN	I-WHO
pain	NN	O-WHO
not	RB	O
requiring	VBG	O
rapid	JJ	O
onset	NN	O
of	IN	O
analgesic	JJ	O
effect	NN	O
,	,	O
the	DT	O
tolerability	NN	O
of	IN	O
ULTRAM®	NNP	O
can	MD	O
be	VB	O
improved	VBN	O
by	IN	O
initiating	VBG	O
therapy	NN	O
with	IN	O
the	DT	O
following	JJ	O
titration	NN	O
regimen	NNS	O
:	:	O
ULTRAM®	NNP	O
should	MD	O
be	VB	O
started	VBN	O
at	IN	O
25	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	B-FREQ
day	NN	O-FREQ
(	(	O
half	JJ	B-DOS
ULTRAM®	NNP	O-DOS
scored	VBD	B-UNIT
tablet	NN	O-UNIT
)	)	O
qAM	NN	O
and	CC	O
titrated	VBN	O
in	IN	O
25	CD	B-DOS
mg	NN	B-UNIT
increments	NNS	O
as	IN	O
separate	JJ	O
doses	NNS	O
every	DT	B-FREQ
3	CD	I-FREQ
days	NNS	O-FREQ
to	TO	O
reach	VB	O
100	CD	B-DOS
mg	JJ	B-UNIT
/	JJ	B-FREQ
day	NN	O-FREQ
(	(	O
25	CD	B-DOS
mg	NN	B-UNIT
q.i.d	NN	O
.	.	O
)	)	O
.	.	O

Instill	NNP	O
one	CD	B-DOS
drop	NN	B-UNIT
into	IN	O
the	DT	O
conjunctival	NN	O
sac	NN	O
(	(	O
s	PRP	O
)	)	O
every	DT	B-FREQ
four	CD	O-FREQ
to	TO	O
six	CD	B-FREQ
hours	NNS	O-FREQ
.	.	O

A	DT	O
small	JJ	O
amount	NN	O
of	IN	O
CENTANY®	NNP	O
ointment	NN	O
should	MD	O
be	VB	O
applied	VBN	O
to	TO	O
the	DT	O
affected	JJ	O
area	NN	O
three	CD	B-FREQ
times	NNS	I-FREQ
daily	RB	O-FREQ
or	CC	O
as	IN	O
directed	VBN	O
by	IN	O
a	DT	O
physician	NN	O
.	.	O

PrandiMet	NN	O
can	MD	O
be	VB	O
administered	VBN	O
2	CD	B-FREQ
to	TO	O
3	CD	B-FREQ
times	NNS	I-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
up	RP	O
to	TO	O
a	DT	O
maximum	JJ	O
daily	JJ	O
dose	NN	O
of	IN	O
10	CD	B-DOS
mg	NNS	B-UNIT
repaglinide	RB	O
/	IN	O
2500	CD	B-DOS
mg	NN	B-UNIT
metformin	NN	O
HCl	NNP	O
.	.	O

VICODIN®	NNP	O
(	(	O
Hydrocodone	NNP	O
Bitartrate	NNP	O
and	CC	O
Acetaminophen	NNP	O
Tablets	NNP	O
,	,	O
USP	NNP	O
5	CD	B-DOS
mg	NN	B-UNIT
/	VBD	O
300	CD	B-DOS
mg	NN	B-UNIT
)	)	O
:	:	O
The	DT	O
usual	JJ	O
adult	NN	B-WHO
dosage	NN	O
is	VBZ	O
one	CD	B-DOS
or	CC	O
two	CD	B-DOS
tablets	NNS	B-UNIT
every	DT	B-FREQ
four	CD	O-FREQ
to	TO	O
six	CD	B-FREQ
hours	NNS	O-FREQ
as	IN	O
needed	VBN	O
for	IN	O
pain	NN	O
.	.	O

Instill	NNP	O
one	CD	B-DOS
drop	NN	B-UNIT
into	IN	O
the	DT	O
conjunctival	JJ	O
sac	NN	O
of	IN	O
the	DT	O
affected	JJ	O
eye	NN	O
4	CD	B-FREQ
times	NNS	I-FREQ
daily	RB	O-FREQ
for	IN	O
14	CD	B-DUR
days	NNS	O-DUR
followed	VBN	O
by	IN	O
tapering	VBG	O
as	IN	O
clinically	RB	O
indicated	VBN	O
.	.	O

The	DT	O
initial	JJ	O
dosage	NN	O
of	IN	O
cortisone	NN	O
acetate	NN	O
may	MD	O
vary	VB	O
from	IN	O
25	CD	B-DOS
to	TO	O
300	CD	B-DOS
mg	NNS	B-UNIT
per	IN	B-FREQ
day	NN	O-FREQ
depending	VBG	O
on	IN	O
the	DT	O
specific	JJ	O
disease	NN	O
entity	NN	O
being	VBG	O
treated	VBN	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
SANCTURA	NNP	O
XR®	NNP	O
is	VBZ	O
one	CD	B-DOS
60	CD	O-DOS
mg	NN	B-UNIT
capsule	NN	O-UNIT
daily	RB	B-FREQ
in	IN	O
the	DT	O
morning	NN	O
.	.	O

The	DT	O
range	NN	O
of	IN	O
initial	JJ	O
doses	NNS	O
is	VBZ	O
0.11	CD	B-DOS
to	TO	O
1.6	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
kg	JJ	O
/	NNP	B-FREQ
day	NN	O-FREQ
in	IN	O
three	CD	B-DOS
or	CC	O
four	CD	B-DOS
divided	VBN	B-UNIT
doses	NNS	O-UNIT
(	(	O
3.2	CD	B-DOS
to	TO	O
48	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
m²bsa	JJ	O
/	NNP	B-FREQ
day	NN	O-FREQ
)	)	O
.	.	O

RETIN	NNP	O
-	:	O
A	DT	O
Gel	NNP	O
,	,	O
Cream	NNP	O
or	CC	O
Liquid	NNP	O
should	MD	O
be	VB	O
applied	VBN	O
once	RB	B-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
,	,	O
before	IN	O
retiring	VBG	O
,	,	O
to	TO	O
the	DT	O
skin	NN	O
where	WRB	O
acne	NN	O
lesions	NNS	O
appear	VBP	O
,	,	O
using	VBG	O
enough	JJ	O
to	TO	O
cover	VB	O
the	DT	O
entire	JJ	O
affected	JJ	O
area	NN	O
lightly	RB	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
DORIBAX®	NNP	O
is	VBZ	O
500	CD	B-DOS
mg	NN	B-UNIT
administered	VBN	O
every	DT	B-FREQ
8	CD	I-FREQ
hours	NNS	O-FREQ
by	IN	O
intravenous	JJ	O
infusion	NN	O
over	IN	O
one	CD	O
hour	NN	O
in	IN	O
patients	NNS	B-WHO
≥	JJ	I-WHO
18	CD	I-WHO
years	NNS	I-WHO
of	IN	I-WHO
age	NN	O-WHO
.	.	O

The	DT	O
usual	JJ	O
dosage	NN	O
is	VBZ	O
30	CD	B-DOS
to	TO	O
50	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
kg	JJ	O
/	NNP	B-FREQ
day	NN	O-FREQ
,	,	O
in	IN	O
equally	RB	O
divided	JJ	O
doses	NNS	O
.	.	O

Breast	NNP	O
cancer	NN	O
:	:	O
160	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	B-FREQ
day	NN	O-FREQ
(	(	O
40	CD	B-DOS
mg	NN	B-UNIT
q.i.d	NN	O
.	.	O
)	)	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
160	CD	B-DOS
mg	NN	B-UNIT
(	(	O
two	CD	B-DOS
80	CD	O-DOS
mg	NNS	B-UNIT
injections	NNS	O-UNIT
)	)	O
at	IN	O
Week	NNP	O
0	CD	O
,	,	O
followed	VBN	O
by	IN	O
80	CD	B-DOS
mg	NNS	B-UNIT
at	IN	O
Weeks	NNP	O
2	CD	O
,	,	O
4	CD	O
,	,	O
6	CD	O
,	,	O
8	CD	O
,	,	O
10	CD	O
,	,	O
and	CC	O
12	CD	O
,	,	O
then	RB	O
80	CD	B-DOS
mg	NNS	B-UNIT
every	DT	B-FREQ
4	CD	I-FREQ
weeks	NNS	O-FREQ
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
PERIKABIVEN®	NNP	O
in	IN	O
adults	NNS	B-WHO
is	VBZ	O
27	CD	B-DOS
to	TO	O
40	CD	B-DOS
mL	NNS	B-UNIT
/	JJ	O
kg	JJ	O
/	NNP	B-FREQ
day	NN	O-FREQ
.	.	O

The	DT	O
usual	JJ	O
adult	NN	B-WHO
dosage	NN	O
of	IN	O
RIDAURA	NNP	O
(	(	O
auranofin	NN	O
)	)	O
is	VBZ	O
6	CD	B-DOS
mg	JJ	B-UNIT
daily	JJ	B-FREQ
,	,	O
given	VBN	O
either	CC	O
as	IN	O
3	CD	B-DOS
mg	JJ	B-UNIT
twice	RB	B-FREQ
daily	RB	O-FREQ
or	CC	O
6	CD	B-DOS
mg	NNS	B-UNIT
once	RB	B-FREQ
daily	RB	O-FREQ
.	.	O

TO	NNP	O
TREAT	NNP	O
THE	NNP	O
EYE	NNP	O
:	:	O
Instill	NNP	O
1	CD	B-DOS
or	CC	O
2	CD	B-DOS
drops	NNS	B-UNIT
every	DT	B-FREQ
3	CD	O-FREQ
or	CC	O
4	CD	B-FREQ
hours	NNS	O-FREQ
,	,	O
or	CC	O
more	RBR	O
frequently	RB	O
as	IN	O
required	VBN	O
.	.	O

Take	VB	O
one	CD	B-DOS
tablet	NN	B-UNIT
by	IN	O
mouth	NN	O
at	IN	O
the	DT	O
same	JJ	O
time	NN	O
every	DT	B-FREQ
day	NN	O-FREQ
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
EPIVIR	NNP	O
in	IN	O
HIV	NNP	O
-	:	O
1	CD	B-DOS
-	:	O
infected	VBN	O
adults	NNS	B-WHO
is	VBZ	O
300	CD	B-DOS
mg	JJ	B-UNIT
daily	RB	B-FREQ
,	,	O
administered	VBN	O
as	IN	O
either	DT	O
150	CD	B-DOS
mg	NN	B-UNIT
taken	VBN	O
orally	RB	O
twice	JJ	B-FREQ
daily	RB	O-FREQ
or	CC	O
300	CD	B-DOS
mg	NNS	B-UNIT
taken	VBN	O
orally	RB	O
once	RB	B-FREQ
daily	JJ	O-FREQ
with	IN	O
or	CC	O
without	IN	O
food	NN	O
.	.	O

CLINDETS®	NNP	O
(	(	O
clindamycin	JJ	O
phosphate	NN	O
pledget	NN	O
)	)	O
should	MD	O
be	VB	O
applied	VBN	O
to	TO	O
areas	NNS	O
affected	VBN	O
by	IN	O
acne	JJ	O
twice	JJ	B-FREQ
daily	RB	O-FREQ
,	,	O
in	IN	O
the	DT	O
morning	NN	O
and	CC	O
at	IN	O
night	NN	O
.	.	O

For	IN	O
treatment	NN	O
of	IN	O
acute	JJ	O
episodes	NNS	O
of	IN	O
bronchospasm	NN	O
or	CC	O
prevention	NN	O
of	IN	O
symptoms	NNS	O
associated	VBN	O
with	IN	O
bronchospasm	NN	O
,	,	O
the	DT	O
recommended	JJ	O
dosage	NN	O
for	IN	O
adults	NNS	B-WHO
and	CC	I-WHO
children	NNS	I-WHO
4	CD	I-WHO
years	NNS	I-WHO
of	IN	I-WHO
age	NN	I-WHO
or	CC	I-WHO
older	JJR	O-WHO
is	VBZ	O
2	CD	B-DOS
inhalations	NNS	B-UNIT
repeated	VBN	O
every	DT	B-FREQ
4	CD	O-FREQ
to	TO	O
6	CD	B-FREQ
hours	NNS	O-FREQ
.	.	O

The	DT	O
dose	NN	O
of	IN	O
GAMUNEX	NNP	O
-	:	O
C	NNP	O
for	IN	O
patients	NNS	O
with	IN	O
PI	NNP	O
is	VBZ	O
300	CD	B-DOS
mg	NN	B-UNIT
/	NN	O
kg	NN	O
to	TO	O
600	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
kg	FW	O
body	NN	O
weight	NN	O
(	(	O
3	CD	B-DOS
mL	NN	B-UNIT
/	NN	O
kg	NN	O
to	TO	O
6	CD	B-DOS
mL	NNS	B-UNIT
/	NNP	O
kg	NN	O
)	)	O
administered	VBD	O
every	DT	B-FREQ
3	CD	O-FREQ
to	TO	O
4	CD	B-FREQ
weeks	NNS	O-FREQ
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
IBRANCE	NNP	O
is	VBZ	O
a	DT	O
125	CD	B-DOS
mg	NN	B-UNIT
capsule	NN	O-UNIT
taken	VBN	O
orally	RB	O
once	RB	B-FREQ
daily	JJ	O-FREQ
for	IN	O
21	CD	B-DUR
consecutive	JJ	I-DUR
days	NNS	O-DUR
followed	VBN	O
by	IN	O
7	CD	B-DUR
days	NNS	O-DUR
off	RB	O
treatment	NN	O
to	TO	O
comprise	VB	O
a	DT	O
complete	JJ	O
cycle	NN	O
of	IN	O
28	CD	O
days	NNS	O
.	.	O

One	CD	B-DOS
RAGWITEK	NNP	B-UNIT
tablet	NN	O-UNIT
daily	RB	B-FREQ
.	.	O

Chlorthalidone	NN	O
is	VBZ	O
usually	RB	O
given	VBN	O
at	IN	O
a	DT	O
dose	NN	O
of	IN	O
25	CD	B-DOS
mg	JJ	B-UNIT
daily	RB	O
;	:	O
the	DT	O
usual	JJ	O
initial	JJ	O
dose	NN	O
of	IN	O
atenolol	NN	O
is	VBZ	O
50	CD	B-DOS
mg	JJ	B-UNIT
daily	RB	B-FREQ
.	.	O

The	DT	O
usual	JJ	O
PLATINOL	NNP	O
dose	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
testicular	JJ	O
cancer	NN	O
in	IN	O
combination	NN	O
with	IN	O
other	JJ	O
approved	VBN	O
chemotherapeutic	JJ	O
agents	NNS	O
is	VBZ	O
20	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
m²	NN	O
IV	NNP	O
daily	RB	B-FREQ
for	IN	O
5	CD	B-DUR
days	NNS	O-DUR
per	IN	O
cycle	NN	O
.	.	O

The	DT	O
SIMPONI	NNP	O
ARIA	NNP	O
dosage	NN	O
regimen	NNS	O
is	VBZ	O
2	CD	B-DOS
mg	NN	B-UNIT
per	IN	O
kg	NN	O
given	VBN	O
as	IN	O
an	DT	O
intravenous	JJ	O
infusion	NN	O
over	IN	O
30	CD	O
minutes	NNS	O
at	IN	O
weeks	NNS	O
0	CD	O
and	CC	O
4	CD	O
,	,	O
then	RB	O
every	DT	B-FREQ
8	CD	I-FREQ
weeks	NNS	O-FREQ
thereafter	RB	O
.	.	O

The	DT	O
maximum	JJ	O
single	JJ	O
recommended	VBN	O
adult	NN	B-WHO
dose	NN	O
of	IN	O
IMITREX	NNP	O
Injection	NNP	O
for	IN	O
the	DT	O
acute	JJ	O
treatment	NN	O
of	IN	O
migraine	NN	O
or	CC	O
cluster	NN	O
headache	NN	O
is	VBZ	O
6	CD	B-DOS
mg	NN	B-UNIT
injected	VBD	O
subcutaneously	RB	O
.	.	O

The	DT	O
usual	JJ	O
starting	NN	O
dose	NN	O
is	VBZ	O
one	CD	B-DOS
drop	NN	B-UNIT
of	IN	O
0.25	CD	O
%	NN	O
TIMOPTIC	NNP	O
in	IN	O
the	DT	O
affected	JJ	O
eye	NN	O
(	(	O
s	JJ	O
)	)	O
twice	RB	B-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
one	CD	B-DOS
applicator	NN	B-UNIT
full	JJ	O
of	IN	O
METROGEL	NNP	O
-	:	O
VAGINAL	NNP	O
(	(	O
approximately	RB	O
5	CD	B-DOS
grams	NNS	B-UNIT
containing	VBG	O
approximately	RB	O
37.5	CD	B-DOS
mg	NNS	B-UNIT
of	IN	O
metronidazole	NN	O
)	)	O
intravaginally	RB	O
once	RB	B-FREQ
or	CC	O
twice	VB	B-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
for	IN	O
5	CD	B-DUR
days	NNS	O-DUR
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
of	IN	O
Focalin	NNP	O
XR	NNP	O
for	IN	O
patients	NNS	B-WHO
who	WP	I-WHO
are	VBP	I-WHO
not	RB	I-WHO
currently	RB	I-WHO
taking	VBG	I-WHO
dexmethylphenidate	NN	I-WHO
or	CC	I-WHO
racemic	JJ	I-WHO
methylphenidate	NN	O-WHO
,	,	O
or	CC	O
for	IN	O
patients	NNS	B-WHO
who	WP	I-WHO
are	VBP	I-WHO
on	IN	I-WHO
stimulants	NNS	I-WHO
other	JJ	I-WHO
than	IN	I-WHO
methylphenidate	NN	O-WHO
,	,	O
is	VBZ	O
5	CD	B-DOS
mg	JJ	B-UNIT
/	NNP	B-FREQ
day	NN	O-FREQ
for	IN	O
pediatric	JJ	B-WHO
patients	NNS	O-WHO
and	CC	O
10	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	B-FREQ
day	NN	O-FREQ
for	IN	O
adult	NN	B-WHO
patients	NNS	O-WHO
.	.	O

The	DT	O
starting	NN	O
dose	NN	O
is	VBZ	O
12.5	CD	B-DOS
mg	NN	B-UNIT
once	RB	B-FREQ
daily	JJ	O-FREQ
or	CC	O
twice	JJ	B-FREQ
daily	RB	O-FREQ
.	.	O

The	DT	O
usual	JJ	O
dosage	NN	O
is	VBZ	O
one	CD	B-DOS
65	CD	O-DOS
mg	NN	B-UNIT
propoxyphene	NN	I-UNIT
hydrochloride	NN	I-UNIT
capsule	NN	O-UNIT
every	DT	B-FREQ
4	CD	I-FREQ
hours	NNS	O-FREQ
as	IN	O
needed	VBN	O
for	IN	O
pain	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
SARAFEM	NNP	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
PMDD	NNP	O
is	VBZ	O
20	CD	B-DOS
mg	JJ	B-UNIT
/	NNP	B-FREQ
day	NN	O-FREQ
given	VBN	O
continuously	RB	O
(	(	O
every	DT	B-FREQ
day	NN	O-FREQ
of	IN	O
the	DT	O
menstrual	JJ	O
cycle	NN	O
)	)	O
or	CC	O
intermittently	RB	O
(	(	O
defined	VBN	O
as	IN	O
starting	VBG	O
a	DT	O
daily	JJ	B-FREQ
dose	JJ	O-FREQ
14	CD	O
days	NNS	O
prior	RB	O
to	TO	O
the	DT	O
anticipated	JJ	O
onset	NN	O
of	IN	O
menstruation	NN	O
through	IN	O
the	DT	O
first	JJ	O
full	JJ	O
day	NN	O
of	IN	O
menses	NNS	O
and	CC	O
repeating	VBG	O
with	IN	O
each	DT	O
new	JJ	O
cycle	NN	O
)	)	O
.	.	O

Usual	JJ	O
dose	NN	O
is	VBZ	O
2	CD	B-DOS
capsules	NNS	B-UNIT
daily	RB	B-FREQ
or	CC	O
as	IN	O
directed	VBN	O
by	IN	O
a	DT	O
physician	NN	O
.	.	O

The	DT	O
daily	JJ	B-FREQ
dose	NN	O
of	IN	O
LOVAZA	NNP	O
is	VBZ	O
4	CD	B-DOS
grams	NNS	B-UNIT
per	IN	B-FREQ
day	NN	O-FREQ
.	.	O

The	DT	O
usual	JJ	O
intravenous	JJ	O
dose	NN	O
is	VBZ	O
1.5	CD	B-DOS
to	TO	O
5	CD	B-DOS
mL	NNS	B-UNIT
per	IN	O
varix	NN	O
.	.	O

15	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
kg	NNP	O
orally	RB	O
every	DT	B-FREQ
4	CD	I-FREQ
hours	NNS	O-FREQ
for	IN	O
6	CD	O
doses	NNS	O
.	.	O

DIFFERIN®	NNP	O
Cream	NNP	O
should	MD	O
be	VB	O
applied	VBN	O
to	TO	O
affected	JJ	O
areas	NNS	O
of	IN	O
the	DT	O
skin	NN	O
,	,	O
once	RB	B-FREQ
daily	JJ	O-FREQ
at	IN	O
nighttime	NN	O
.	.	O

TOBI	NNP	O
Podhaler	NNP	O
is	VBZ	O
administered	VBN	O
twice	RB	B-FREQ
-	:	O
daily	JJ	B-FREQ
in	IN	O
alternating	VBG	O
periods	NNS	O
of	IN	O
28	CD	O
days	NNS	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
in	IN	O
adult	NN	B-WHO
patients	NNS	O
with	IN	B-WHO
hypertension	NN	I-WHO
taking	VBG	I-WHO
diuretics	NNS	O-WHO
is	VBZ	O
5	CD	B-DOS
mg	NN	B-UNIT
once	RB	O
per	IN	B-FREQ
day	NN	O-FREQ
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
BAVENCIO	NNP	O
is	VBZ	O
10	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
kg	NN	O
administered	VBD	O
as	IN	O
an	DT	O
intravenous	JJ	O
infusion	NN	O
over	IN	O
60	CD	O
minutes	NNS	O
every	DT	B-FREQ
2	CD	I-FREQ
weeks	NNS	O-FREQ
until	IN	O
disease	JJ	O
progression	NN	O
or	CC	O
unacceptable	JJ	O
toxicity	NN	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
is	VBZ	O
300	CD	B-DOS
mg	NN	B-UNIT
once	RB	B-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
for	IN	O
30	CD	B-DUR
days	NNS	O-DUR
,	,	O
followed	VBD	O
thereafter	RB	O
by	IN	O
150	CD	B-DOS
mg	NN	B-UNIT
once	RB	B-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
.	.	O

The	DT	O
recommended	JJ	O
initial	JJ	O
dose	NN	O
of	IN	O
AVAPRO	NNP	O
is	VBZ	O
150	CD	B-DOS
mg	NN	B-UNIT
once	RB	B-FREQ
daily	RB	O-FREQ
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
ProstaScint®	NNP	O
(	(	O
c	JJ	O
apromab	RB	O
pendetide	NN	O
)	)	O
is	VBZ	O
0.5	CD	B-DOS
mg	NN	B-UNIT
radiolabeled	VBD	O
with	IN	O
5	CD	B-DOS
mCi	NNS	B-UNIT
of	IN	O
Indium	NNP	O
In	IN	O
111	CD	O
chloride	NN	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
of	IN	O
LIPITOR	NNP	O
is	VBZ	O
10	CD	B-DOS
or	CC	O
20	CD	B-DOS
mg	NNS	B-UNIT
once	RB	B-FREQ
daily	RB	O-FREQ
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
TYKERB	NNP	O
is	VBZ	O
1250	CD	B-DOS
mg	NN	B-UNIT
given	VBN	O
orally	RB	O
once	RB	B-FREQ
daily	JJ	O-FREQ
on	IN	O
Days	NNS	O
1	CD	O
-	:	O
21	CD	O
continuously	RB	O
in	IN	O
combination	NN	O
with	IN	O
capecitabine	JJ	O
2000	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
m²	NN	O
/	NNP	B-FREQ
day	NN	O-FREQ
(	(	O
administered	VBN	O
orally	RB	O
in	IN	O
2	CD	B-DOS
doses	NNS	B-UNIT
approximately	RB	O
12	CD	O
hours	NNS	O
apart	RB	O
)	)	O
on	IN	O
Days	$	O
1	CD	O
-	:	O
14	CD	O
in	IN	O
a	DT	O
repeating	VBG	O
21	CD	O
-	:	O
day	NN	O
cycle	NN	O
.	.	O

A	DT	O
dose	NN	O
of	IN	O
50	CD	B-DOS
mg	NNS	B-UNIT
once	RB	B-FREQ
daily	JJ	O-FREQ
is	VBZ	O
recommended	VBN	O
for	IN	O
most	JJS	B-WHO
patients	NNS	O-WHO
.	.	O

The	DT	O
maximum	NN	O
recommended	JJ	O
dosage	NN	O
is	VBZ	O
9	CD	B-DOS
breaths	NNS	B-UNIT
per	IN	O
treatment	NN	O
session	NN	O
,	,	O
4	CD	B-FREQ
times	NNS	I-FREQ
daily	RB	O-FREQ
.	.	O

Instill	NNP	O
four	CD	B-DOS
drops	NNS	B-UNIT
into	IN	O
the	DT	O
affected	JJ	O
ear	NN	O
(	(	O
s	PRP	O
)	)	O
twice	RB	B-FREQ
daily	RB	O-FREQ
for	IN	O
seven	CD	B-DUR
days	NNS	O-DUR
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
FUZEON	NNP	O
is	VBZ	O
90	CD	B-DOS
mg	NN	B-UNIT
(	(	O
1	CD	B-DOS
mL	NN	B-UNIT
)	)	O
twice	RB	B-FREQ
daily	RB	O-FREQ
injected	VBN	O
subcutaneously	RB	O
into	IN	O
the	DT	O
upper	JJ	O
arm	NN	O
,	,	O
anterior	JJ	O
thigh	NN	O
or	CC	O
abdomen	NNS	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
SIVEXTRO	NNP	O
is	VBZ	O
200	CD	B-DOS
mg	NN	B-UNIT
administered	VBN	O
once	RB	B-FREQ
daily	JJ	O-FREQ
for	IN	O
six	CD	B-DUR
(	(	O
6	CD	B-DUR
)	)	O
days	NNS	B-DUR
either	CC	O
orally	RB	O
(	(	O
with	IN	O
or	CC	O
without	IN	O
food	NN	O
)	)	O
or	CC	O
as	IN	O
an	DT	O
intravenous	JJ	O
(	(	O
IV	NNP	O
)	)	O
infusion	NN	O
in	IN	O
patients	NNS	B-WHO
18	CD	I-WHO
years	NNS	I-WHO
of	IN	I-WHO
age	NN	I-WHO
or	CC	I-WHO
older	JJR	O-WHO
.	.	O

The	DT	O
usual	JJ	O
recommended	VBD	O
starting	VBG	O
dose	NN	O
for	IN	O
oral	JJ	O
administration	NN	O
is	VBZ	O
2	CD	B-DOS
mg	NN	B-UNIT
.	.	O

A	DT	O
1000	CD	O
second	NN	O
(	(	O
16	CD	O
minutes	NNS	O
40	CD	O
seconds	NNS	O
)	)	O
exposure	NN	O
is	VBZ	O
required	VBN	O
to	TO	O
provide	VB	O
a	DT	O
10	CD	O
J	NNP	O
/	NNP	O
cm²	NN	O
light	NN	O
dose	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
BELVIQ	NNP	O
is	VBZ	O
10	CD	B-DOS
mg	NN	B-UNIT
administered	VBN	O
orally	RB	O
twice	JJ	B-FREQ
daily	RB	O-FREQ
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dosage	NN	O
of	IN	O
SPRYCEL	NNP	O
for	IN	O
chronic	JJ	O
phase	NN	O
CML	NNP	O
is	VBZ	O
100	CD	B-DOS
mg	NN	B-UNIT
administered	VBN	O
orally	RB	O
once	RB	B-FREQ
daily	JJ	O-FREQ
.	.	O

Apply	VB	O
a	DT	O
thin	JJ	O
film	NN	O
of	IN	O
ACLOVATE®	NNP	O
(	(	O
alclometasone	JJ	O
dipropionate	NN	O
)	)	O
Cream	NN	O
or	CC	O
Ointment	NN	O
to	TO	O
the	DT	O
affected	JJ	O
skin	NN	O
areas	NNS	O
2	CD	B-FREQ
or	CC	O
3	CD	B-FREQ
times	NNS	I-FREQ
daily	RB	O-FREQ
;	:	O
massage	VB	O
gently	RB	O
until	IN	O
the	DT	O
medication	NN	O
disappears	VBZ	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
one	CD	B-DOS
drop	NN	B-UNIT
in	IN	O
the	DT	O
effected	VBN	O
eye	NN	O
up	RB	O
to	TO	O
four	CD	B-FREQ
times	NNS	I-FREQ
daily	RB	O-FREQ
.	.	O

Apply	VB	O
a	DT	O
thin	JJ	O
layer	NN	O
(	(	O
1	CD	B-DOS
drop	NN	B-UNIT
covers	VBZ	O
an	DT	O
area	NN	O
of	IN	O
skin	$	O
2	CD	O
inches	NNS	O
by	IN	O
2	CD	O
inches	NNS	O
)	)	O
to	TO	O
the	DT	O
affected	JJ	O
area	NN	O
3	CD	O
-	:	O
4	CD	O
times	NNS	O
over	IN	O
a	DT	O
24	CD	O
-	:	O
hour	NN	O
period	NN	O
,	,	O
or	CC	O
as	IN	O
directed	VBN	O
by	IN	O
a	DT	O
physician	NN	O
,	,	O
and	CC	O
rub	NN	O
in	IN	O
gently	RB	O
.	.	O

It	PRP	O
is	VBZ	O
recommended	VBN	O
that	IN	O
MYCOBUTIN	NNP	O
Capsules	NNP	O
be	VB	O
administered	VBN	O
at	IN	O
a	DT	O
dose	NN	O
of	IN	O
300	CD	B-DOS
mg	NNS	B-UNIT
once	RB	B-FREQ
daily	RB	O-FREQ
.	.	O

Instill	NNP	O
one	CD	B-DOS
drop	NN	B-UNIT
into	IN	O
the	DT	O
conjunctival	JJ	O
sac	NN	O
two	CD	B-FREQ
to	TO	O
four	CD	B-FREQ
times	NNS	I-FREQ
daily	RB	O-FREQ
.	.	O

Usual	JJ	O
Pediatric	NNP	whO
Dosage	NN	O
:	:	O
0.25	CD	B-DOS
to	TO	O
0.5	CD	B-DOS
mL	NNS	B-UNIT
/	JJ	O
kg	NN	O
of	IN	O
body	NN	O
weight	VBD	O
1	CD	B-FREQ
to	TO	O
4	CD	B-FREQ
times	NNS	I-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
.	.	O

PREMPRO	NNP	O
therapy	NN	O
consists	VBZ	O
of	IN	O
a	DT	O
single	JJ	B-DOS
tablet	NN	B-UNIT
to	TO	O
be	VB	O
taken	VBN	O
orally	RB	O
once	RB	B-FREQ
daily	JJ	O-FREQ
.	.	O

The	DT	O
usual	JJ	O
dosage	NN	O
range	NN	O
of	IN	O
enalapril	NN	O
is	VBZ	O
10	CD	B-DOS
to	TO	O
40	CD	B-DOS
mg	NNS	B-UNIT
per	IN	B-FREQ
day	NN	O-FREQ
administered	VBN	O
in	IN	O
a	DT	O
single	JJ	B-DOS
or	CC	O
two	CD	B-DOS
divided	JJ	B-UNIT
doses	NNS	O-UNIT
.	.	O

A	DT	O
single	JJ	B-DOS
intravenous	JJ	B-UNIT
dose	NN	O-UNIT
of	IN	O
ACTHREL®	NNP	O
at	IN	O
1	CD	O
mcg	NN	O
/	NNP	O
kg	NN	O
is	VBZ	O
recommended	VBN	O
for	IN	O
the	DT	O
testing	NN	O
of	IN	O
pituitary	JJ	O
corticotrophin	NN	O
function	NN	O
.	.	O

The	DT	O
usual	JJ	O
starting	NN	O
dose	NN	O
is	VBZ	O
Diovan	NNP	O
HCT	NNP	O
160	CD	O
/	VBD	O
12.5	CD	B-DOS
mg	NN	B-UNIT
once	RB	B-FREQ
daily	RB	O-FREQ
.	.	O

Start	NNP	O
dosing	VBG	O
with	IN	O
45	CD	B-DOS
mg	NNS	B-UNIT
once	RB	B-FREQ
daily	RB	O-FREQ
.	.	O

Adults	NNS	B-WHO
:	:	O
The	DT	O
usual	JJ	O
dose	NN	O
of	IN	O
oral	JJ	O
doxycycline	NN	O
is	VBZ	O
200	CD	B-DOS
mg	NN	B-UNIT
on	IN	O
the	DT	O
first	JJ	O
day	NN	O
of	IN	O
treatment	NN	O
(	(	O
administered	VBN	O
100	CD	B-DOS
mg	NN	B-UNIT
every	DT	B-FREQ
12	CD	I-FREQ
hours	NNS	O-FREQ
)	)	O
,	,	O
followed	VBN	O
by	IN	O
a	DT	O
maintenance	NN	O
dose	NN	O
of	IN	O
100	CD	B-DOS
mg	JJ	B-UNIT
daily	RB	B-FREQ
.	.	O

The	DT	O
usual	JJ	O
adult	NN	B-WHO
dose	NN	O
is	VBZ	O
1	CD	B-DOS
or	CC	O
2	CD	B-DOS
tablets	NNS	B-UNIT
(	(	O
25	CD	B-DOS
or	CC	O
50	CD	B-DOS
mg	NN	B-UNIT
)	)	O
4	CD	B-FREQ
times	NNS	I-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
preferably	RB	O
with	IN	O
meals	NNS	O
and	CC	O
at	IN	O
bedtime	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
for	IN	O
Actigall	NNP	O
treatment	NN	O
of	IN	O
radiolucent	JJ	O
gallbladder	NN	O
stones	NNS	O
is	VBZ	O
8	CD	B-DOS
-	:	O
10	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
kg	NN	O
/	NNP	B-FREQ
day	NN	O-FREQ
given	VBN	O
in	IN	O
2	CD	B-DOS
or	CC	O
3	CD	B-DOS
divided	JJ	B-UNIT
doses	NNS	O-UNIT
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
ADDYI	NNP	O
is	VBZ	O
100	CD	B-DOS
mg	NN	B-UNIT
administered	VBN	O
orally	RB	O
once	RB	B-FREQ
per	IN	I-FREQ
day	NN	O-FREQ
at	IN	O
bedtime	NN	O
.	.	O

The	DT	O
recommended	JJ	O
loading	NN	O
dose	NN	O
of	IN	O
SOMAVERT	NNP	O
is	VBZ	O
40	CD	B-DOS
mg	NN	B-UNIT
given	VBN	O
subcutaneously	RB	O
,	,	O
under	IN	O
healthcare	NN	O
provider	NN	O
supervision	NN	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
for	IN	O
patients	NNS	B-WHO
without	IN	I-WHO
congestive	JJ	I-WHO
heart	NN	I-WHO
failure	NN	O-WHO
is	VBZ	O
15	CD	B-DOS
mg	NN	B-UNIT
or	CC	O
30	CD	B-DOS
mg	NNS	B-UNIT
once	RB	B-FREQ
daily	RB	O-FREQ
.	.	O

The	DT	O
usual	JJ	O
dose	NN	O
for	IN	O
adults	NNS	B-WHO
and	CC	I-WHO
children	NNS	I-WHO
12	CD	I-WHO
years	NNS	I-WHO
and	CC	I-WHO
older	JJR	O-WHO
is	VBZ	O
two	CD	B-DOS
inhalations	NNS	B-UNIT
(	(	O
400	CD	B-DOS
mcg	NN	B-UNIT
)	)	O
repeated	VBD	O
every	DT	B-FREQ
4	CD	O-FREQ
-	:	O
6	CD	B-FREQ
hours	NNS	O-FREQ
.	.	O

One	CD	B-DOS
tablet	NN	B-UNIT
three	CD	B-FREQ
or	CC	O
four	CD	B-FREQ
times	NNS	I-FREQ
daily	RB	O-FREQ
.	.	O

Initiate	NNP	O
dosing	NN	O
at	IN	O
50	CD	B-DOS
mg	JJ	B-UNIT
twice	RB	B-FREQ
daily	RB	O-FREQ
.	.	O

The	DT	O
recommended	JJ	O
starting	VBG	O
daily	JJ	B-FREQ
dose	NN	O
of	IN	O
BANZEL	NNP	O
in	IN	O
pediatric	JJ	B-WHO
patients	NNS	O-WHO
with	IN	O
Lennox	NNP	O
-	:	O
Gastaut	NNP	O
Syndrome	NNP	O
is	VBZ	O
approximately	RB	O
10	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
kg	NN	O
administered	VBN	O
in	IN	O
two	CD	B-DOS
equally	RB	B-UNIT
divided	JJ	I-UNIT
doses	NNS	O-UNIT
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
Vectibix	NNP	O
is	VBZ	O
6	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
kg	NN	O
,	,	O
administered	VBN	O
as	IN	O
an	DT	O
intravenous	JJ	O
infusion	NN	O
over	IN	O
60	CD	O
minutes	NNS	O
,	,	O
every	DT	B-FREQ
14	CD	I-FREQ
days	NNS	O-FREQ
.	.	O

Apply	VB	O
a	DT	O
thin	JJ	O
film	NN	O
of	IN	O
Topicort®	NNP	O
(	(	O
desoximetasone	NN	O
)	)	O
Ointment	NNP	O
USP	NNP	O
,	,	O
0.05	CD	O
%	NN	O
to	TO	O
the	DT	O
affected	JJ	O
skin	NN	O
areas	NNS	O
twice	RB	B-FREQ
daily	RB	O-FREQ
.	.	O

The	DT	O
adult	NN	B-WHO
starting	VBG	O
dose	NN	O
is	VBZ	O
50	CD	B-DOS
to	TO	O
75	CD	B-DOS
mg	NN	B-UNIT
of	IN	O
the	DT	O
drug	NN	O
daily	RB	B-FREQ
,	,	O
together	RB	O
with	IN	O
1	CD	B-DOS
to	TO	O
4	CD	B-DOS
g	JJ	B-UNIT
daily	RB	B-FREQ
of	IN	O
a	DT	O
sulfonamide	NN	O
of	IN	O
the	DT	O
sulfapyrimidine	NN	O
type	NN	O
,	,	O
e.g	NN	O
.	.	O
sufadoxine	NN	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
of	IN	O
IMDUR	NNP	O
Tablets	NNP	O
is	VBZ	O
30	CD	B-DOS
mg	NN	B-UNIT
(	(	O
given	VBN	O
as	IN	O
a	DT	O
single	JJ	B-DOS
30	CD	O-DOS
mg	JJ	B-UNIT
tablet	NN	O-UNIT
or	CC	O
as	IN	O
1	CD	O
/	$	O
2	CD	O
/	JJ	O
18	CD	O
of	IN	O
a	DT	O
60	CD	B-DOS
mg	JJ	B-UNIT
tablet	NN	O-UNIT
)	)	O
or	CC	O
60	CD	B-DOS
mg	NN	B-UNIT
(	(	O
given	VBN	O
as	IN	O
a	DT	O
single	JJ	B-DOS
tablet	NN	B-UNIT
)	)	O
once	RB	B-FREQ
daily	JJ	O-FREQ
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
400	CD	B-DOS
mg	NN	B-UNIT
orally	RB	O
once	RB	B-FREQ
daily	JJ	O-FREQ
with	IN	O
food	NN	O
.	.	O

The	DT	O
recommended	JJ	O
initial	JJ	O
dose	NN	O
of	IN	O
MENOPUR®	NNP	O
for	IN	O
women	NNS	O
who	WP	O
have	VBP	O
received	VBN	O
a	DT	O
GnRH	NNP	O
agonist	NN	O
for	IN	O
pituitary	JJ	O
suppression	NN	O
is	VBZ	O
225	CD	B-DOS
International	NNP	B-UNIT
Units	NNP	O-UNIT
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
XIFAXAN	NNP	O
is	VBZ	O
one	CD	B-DOS
200	CD	O-DOS
mg	NN	B-UNIT
tablet	NN	O-UNIT
taken	VBN	O
orally	RB	O
three	CD	B-FREQ
times	NNS	I-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
for	IN	O
3	CD	B-DUR
days	NNS	O-DUR
.	.	O

0.1	CD	B-DOS
mg	JJ	B-UNIT
tablet	NN	O-UNIT
twice	RB	B-FREQ
daily	RB	O-FREQ
(	(	O
morning	NN	O
and	CC	O
bedtime	NN	O
)	)	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
LUPRON	NNP	O
DEPOT	NNP	O
is	VBZ	O
7.5	CD	B-DOS
mg	NN	B-UNIT
for	IN	O
1	CD	B-DUR
-	:	O
month	NN	B-DUR
administration	NN	O
,	,	O
incorporated	VBN	O
in	IN	O
a	DT	O
depot	NN	O
formulation	NN	O
.	.	O

The	DT	O
usual	JJ	O
adult	NN	B-WHO
dosage	NN	O
is	VBZ	O
one	CD	B-DOS
tablet	NN	B-UNIT
every	DT	B-FREQ
four	CD	O-FREQ
to	TO	O
six	CD	B-FREQ
hours	NNS	O-FREQ
as	IN	O
needed	VBN	O
for	IN	O
pain	NN	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dosage	NN	O
of	IN	O
Trental	NNP	O
(	(	O
pentoxifylline	NN	O
)	)	O
is	VBZ	O
400	CD	B-DOS
mg	JJ	B-UNIT
twice	RB	B-FREQ
daily	RB	O-FREQ
after	IN	O
meals	NNS	O
.	.	O

Initiate	NNP	O
treatment	NN	O
with	IN	O
a	DT	O
daily	JJ	B-FREQ
dose	NN	O
of	IN	O
1000	CD	B-DOS
mg	JJ	B-UNIT
/	NNP	B-FREQ
day	NN	O-FREQ
,	,	O
given	VBN	O
as	IN	O
twice	RB	B-FREQ
-	:	O
daily	JJ	B-FREQ
dosing	NN	O
(	(	O
500	CD	B-DOS
mg	NN	B-UNIT
twice	RB	B-FREQ
daily	RB	O-FREQ
)	)	O
.	.	O

The	DT	O
recommended	JJ	O
dosing	NN	O
for	IN	O
ORBACTIV	NNP	O
is	VBZ	O
a	DT	O
single	JJ	B-DOS
1200	CD	O-DOS
mg	NN	B-UNIT
dose	NN	O-UNIT
administered	VBN	O
by	IN	O
intravenous	JJ	O
infusion	NN	O
over	IN	O
3	CD	O
hours	NNS	O
in	IN	O
patients	NNS	B-WHO
18	CD	I-WHO
years	NNS	I-WHO
and	CC	I-WHO
older	JJR	O-WHO
.	.	O

Adults	NNS	B-WHO
and	CC	I-WHO
pediatric	JJ	I-WHO
patients	NNS	I-WHO
12	CD	I-WHO
years	NNS	I-WHO
of	IN	I-WHO
age	NN	I-WHO
and	CC	I-WHO
older	JJR	O-WHO
:	:	O
1	CD	B-DOS
to	TO	O
2	CD	B-DOS
tablets	NNS	B-UNIT
every	DT	B-FREQ
four	CD	I-FREQ
hours	NNS	O-FREQ
or	CC	O
as	IN	O
needed	VBN	O
.	.	O

The	DT	O
recommended	VBN	O
adult	NN	B-WHO
dose	NN	O
of	IN	O
Fludarabine	NNP	O
Phosphate	NNP	O
Injection	NNP	O
is	VBZ	O
25	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
m²	NN	O
diluted	VBD	O
in	IN	O
100	CD	B-DOS
to	TO	O
125	CD	B-DOS
cc	NN	B-UNIT
of	IN	O
5	CD	O
%	NN	O
dextrose	JJ	O
injection	NN	O
USP	NNP	O
or	CC	O
0.9	CD	O
%	NN	O
sodium	NN	O
chloride	NN	O
USP	NNP	O
administered	VBD	O
intravenously	RB	O
over	IN	O
a	DT	O
period	NN	O
of	IN	O
approximately	RB	O
30	CD	O
minutes	NNS	O
daily	RB	B-FREQ
for	IN	O
five	CD	B-DUR
consecutive	JJ	I-DUR
days	NNS	O-DUR
.	.	O

The	DT	O
suggested	JJ	O
total	JJ	O
daily	JJ	B-FREQ
dose	NN	O
ranges	VBZ	O
between	IN	O
3	CD	B-DOS
to	TO	O
6	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	B-FREQ
day	NN	O-FREQ
.	.	O

Adults	NNS	B-WHO
and	CC	I-WHO
children	NNS	I-WHO
12	CD	I-WHO
years	NNS	I-WHO
of	IN	I-WHO
age	NN	I-WHO
and	CC	I-WHO
older	JJR	O-WHO
:	:	O
One	CD	B-DOS
capsule	NN	B-UNIT
every	DT	B-FREQ
12	CD	I-FREQ
hours	NNS	O-FREQ
,	,	O
not	RB	O
to	TO	O
exceed	VB	O
2	CD	B-DOS
capsules	NNS	B-UNIT
in	IN	O
24	CD	O
hours	NNS	O
.	.	O

Adults	NNS	B-WHO
and	CC	I-WHO
Children	NNP	I-WHO
over	IN	I-WHO
10	CD	I-WHO
years	NNS	I-WHO
of	IN	I-WHO
age	NN	O-WHO
:	:	O
Usual	JJ	O
dose	NN	O
is	VBZ	O
one	CD	B-DOS
100	CD	O-DOS
mg	NN	B-UNIT
or	CC	O
200	CD	B-DOS
mg	NN	B-UNIT
capsule	NN	O-UNIT
three	CD	B-FREQ
times	NNS	I-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
as	IN	O
needed	VBN	O
for	IN	O
cough	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
INFLECTRA	NNP	O
is	VBZ	O
5	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
kg	VB	O
given	VBN	O
as	IN	O
an	DT	O
intravenous	JJ	O
induction	NN	O
regimen	NNS	O
at	IN	O
0	CD	O
,	,	O
2	CD	O
and	CC	O
6	CD	O
weeks	NNS	O
followed	VBN	O
by	IN	O
a	DT	O
maintenance	NN	O
regimen	NN	O
of	IN	O
5	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
kg	NN	O
every	DT	B-FREQ
6	CD	I-FREQ
weeks	NNS	O-FREQ
thereafter	RB	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
active	JJ	O
ankylosing	VBG	O
spondylitis	NN	O
.	.	O

10	CD	B-DOS
mL	NN	B-UNIT
every	DT	B-FREQ
4	CD	O-FREQ
to	TO	O
6	CD	B-FREQ
hours	NNS	O-FREQ
,	,	O
not	RB	O
to	TO	O
exceed	VB	O
6	CD	B-DOS
doses	NNS	B-UNIT
(	(	O
60	CD	B-DOS
mL	NN	B-UNIT
)	)	O
in	IN	O
24	CD	O
hours	NNS	O
.	.	O

The	DT	O
usual	JJ	O
adult	NN	B-WHO
daily	RB	B-FREQ
dose	NN	O
of	IN	O
CEFOBID	NNP	O
(	(	O
sterile	JJ	O
cefoperazone	NN	O
)	)	O
is	VBZ	O
2	CD	B-DOS
to	TO	O
4	CD	B-DOS
grams	NNS	B-UNIT
per	IN	B-FREQ
day	NN	O-FREQ
administered	VBN	O
in	IN	O
equally	RB	O
divided	JJ	O
doses	NNS	O
every	DT	B-FREQ
12	CD	I-FREQ
hours	NNS	O-FREQ
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
for	IN	O
adults	NNS	B-WHO
is	VBZ	O
1200	CD	B-DOS
mg	NN	B-UNIT
administered	VBN	O
in	IN	O
two	CD	B-DOS
divided	JJ	B-UNIT
doses	NNS	O-UNIT
30	CD	O
minutes	NNS	O
before	IN	O
the	DT	O
morning	NN	O
and	CC	O
evening	NN	O
meals	NNS	O
.	.	O

The	DT	O
initial	JJ	O
dosage	NN	O
of	IN	O
CELESTONE	NNP	O
Syrup	NNP	O
(	(	O
betamethasone	NN	O
)	)	O
may	MD	O
vary	VB	O
from	IN	O
0.6	CD	B-DOS
mg	NNS	B-UNIT
to	TO	O
7.2	CD	B-DOS
mg	NNS	B-UNIT
per	IN	B-FREQ
day	NN	O-FREQ
depending	VBG	O
on	IN	O
the	DT	O
specific	JJ	O
disease	NN	O
entity	NN	O
being	VBG	O
treated	VBN	O
.	.	O

Apply	VB	O
a	DT	O
thin	JJ	O
film	NN	O
of	IN	O
Desoximetasone	NNP	O
Ointment	NNP	O
to	TO	O
the	DT	O
affected	JJ	O
skin	NN	O
areas	NNS	O
twice	RB	B-FREQ
daily	RB	O-FREQ
.	.	O

Initial	JJ	O
dosage	NN	O
of	IN	O
MIRADON	NNP	O
(	(	O
anisindione	NN	O
)	)	O
Tablets	NNPS	O
is	VBZ	O
300	CD	B-DOS
mg	NN	B-UNIT
the	DT	O
first	JJ	O
day	NN	O
,	,	O
200	CD	B-DOS
mg	VBD	B-UNIT
the	DT	O
second	JJ	O
day	NN	O
,	,	O
and	CC	O
100	CD	B-DOS
mg	NN	B-UNIT
the	DT	O
third	JJ	O
day	NN	O
.	.	O

The	DT	O
initial	JJ	O
dose	NN	O
is	VBZ	O
35	CD	B-DOS
to	TO	O
105	CD	B-DOS
mg	NNS	B-UNIT
per	IN	B-FREQ
day	NN	O-FREQ
.	.	O

Apply	VB	O
a	DT	O
thin	JJ	O
film	NN	O
of	IN	O
PANDEL	NNP	O
to	TO	O
the	DT	O
affected	JJ	O
area	NN	O
once	RB	B-FREQ
or	CC	O
twice	VB	B-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
depending	VBG	O
on	IN	O
the	DT	O
severity	NN	O
of	IN	O
the	DT	O
condition	NN	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
ZEPATIER	NNP	O
is	VBZ	O
one	CD	B-DOS
tablet	NN	B-UNIT
taken	VBN	O
orally	RB	O
once	RB	B-FREQ
daily	JJ	O-FREQ
with	IN	O
or	CC	O
without	IN	O
food	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
DURLAZA	NNP	O
is	VBZ	O
one	CD	B-DOS
capsule	NN	B-UNIT
(	(	O
162.5	CD	B-DOS
mg	NN	B-UNIT
)	)	O
once	RB	B-FREQ
daily	JJ	O-FREQ
.	.	O

Adults	NNS	B-WHO
:	:	O
The	DT	O
usual	JJ	O
recommended	JJ	O
dosage	NN	O
for	IN	O
systemic	JJ	O
and	CC	O
urinary	JJ	O
tract	NN	O
infections	NNS	O
for	IN	O
average	NN	O
(	(	O
60	CD	O
kg	NN	O
)	)	O
adults	NNS	B-WHO
is	VBZ	O
3.1	CD	B-DOS
grams	NNS	B-UNIT
of	IN	O
TIMENTIN	NNP	O
(	(	O
3.1	CD	B-DOS
-	:	O
gram	NN	B-UNIT
vial	JJ	O-UNIT
containing	VBG	O
3	CD	B-DOS
grams	NNS	B-UNIT
ticarcillin	NN	O
and	CC	O
100	CD	B-DOS
mg	NN	B-UNIT
clavulanic	JJ	O
acid	NN	O
)	)	O
given	VBN	O
every	DT	B-FREQ
4	CD	O-FREQ
to	TO	O
6	CD	B-FREQ
hours	NNS	O-FREQ
.	.	O

Initiate	NNP	O
therapy	NN	O
with	IN	O
HYSINGLA	NNP	O
ER	NNP	O
20	CD	B-DOS
mg	NN	B-UNIT
orally	RB	O
every	DT	B-FREQ
24	CD	I-FREQ
hours	NNS	O-FREQ
.	.	O

The	DT	O
maximum	NN	O
recommended	VBD	O
daily	JJ	B-FREQ
oral	JJ	O
dose	NN	O
of	IN	O
VIVLODEX	NNP	O
is	VBZ	O
10	CD	B-DOS
mg	NN	B-UNIT
.	.	O

The	DT	O
recommended	JJ	O
MOVANTIK	NNP	O
dosage	NN	O
is	VBZ	O
25	CD	B-DOS
mg	NN	B-UNIT
once	RB	B-FREQ
daily	RB	O-FREQ
in	IN	O
the	DT	O
morning	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
LUPRON	NNP	O
DEPOT	NNP	O
22.5	CD	B-DOS
mg	NN	B-UNIT
for	IN	O
3	CD	B-DUR
-	:	O
month	NN	B-DUR
administration	NN	O
is	VBZ	O
one	CD	B-DOS
injection	NN	B-UNIT
every	DT	B-FREQ
12	CD	I-FREQ
weeks	NNS	O-FREQ
.	.	O

The	DT	O
usual	JJ	O
starting	NN	O
and	CC	O
maintenance	NN	O
dose	NN	O
of	IN	O
levatol®	NN	O
,	,	O
used	VBD	O
alone	RB	O
or	CC	O
in	IN	O
combination	NN	O
with	IN	O
other	JJ	O
antihypertensive	JJ	O
agents	NNS	O
,	,	O
such	JJ	O
as	IN	O
thiazide	JJ	O
-	:	O
type	NN	O
diuretics	NNS	O
,	,	O
is	VBZ	O
20	CD	B-DOS
mg	NN	B-UNIT
given	VBN	O
once	RB	B-FREQ
daily	JJ	O-FREQ
.	.	O

It	PRP	O
is	VBZ	O
recommended	VBN	O
that	IN	O
Adalat	NNP	O
CC	NNP	O
be	VB	O
administered	VBN	O
orally	RB	O
once	RB	B-FREQ
daily	JJ	O-FREQ
on	IN	O
an	DT	O
empty	JJ	O
stomach	NN	O
.	.	O

ADVAIR	NNP	O
HFA	NNP	O
should	MD	O
be	VB	O
administered	VBN	O
as	IN	O
2	CD	B-DOS
inhalations	NNS	B-UNIT
twice	RB	B-FREQ
daily	RB	O-FREQ
by	IN	O
the	DT	O
orally	RB	O
inhaled	VBN	O
route	NN	O
only	RB	O
.	.	O

WESTCORT	NNP	O
CREAM	NNP	O
(	(	O
hydrocortisone	NN	O
valerate	NN	O
cream	NN	O
)	)	O
should	MD	O
be	VB	O
applied	VBN	O
to	TO	O
the	DT	O
affected	JJ	O
area	NN	O
as	IN	O
a	DT	O
thin	JJ	O
film	NN	O
two	CD	B-FREQ
or	CC	O
three	CD	B-FREQ
times	NNS	I-FREQ
daily	RB	O-FREQ
depending	VBG	O
on	IN	O
the	DT	O
severity	NN	O
of	IN	O
the	DT	O
condition	NN	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
CERDELGA	NNP	O
is	VBZ	O
84	CD	B-DOS
mg	JJ	B-UNIT
twice	RB	B-FREQ
daily	RB	O-FREQ
in	IN	O
CYP2D6	NNP	O
EMs	NNP	O
and	CC	O
IMs	NNP	O
.	.	O

The	DT	O
recommended	VBN	O
adult	NN	B-WHO
oral	JJ	O
dose	NN	O
of	IN	O
Cytotec	NNP	O
for	IN	O
reducing	VBG	O
the	DT	O
risk	NN	O
of	IN	O
NSAID	NNP	O
-	:	O
induced	VBD	O
gastric	JJ	O
ulcers	NNS	O
is	VBZ	O
200	CD	B-DOS
mcg	NN	B-UNIT
four	CD	B-FREQ
times	NNS	I-FREQ
daily	RB	O-FREQ
with	IN	O
food	NN	O
.	.	O

Usual	JJ	O
dose	NN	O
is	VBZ	O
2	CD	B-DOS
capsules	NNS	B-UNIT
daily	RB	B-FREQ
or	CC	O
as	IN	O
directed	VBN	O
by	IN	O
a	DT	O
physician	NN	O
.	.	O

Each	DT	O
MENVEO	NNP	O
dose	NN	O
should	MD	O
be	VB	O
administered	VBN	O
as	IN	O
a	DT	O
single	JJ	B-DOS
0.5	CD	O-DOS
mL	NN	B-UNIT
intramuscular	JJ	O
injection	NN	B-UNIT
,	,	O
preferably	RB	O
into	IN	O
the	DT	O
anterolateral	JJ	O
aspect	NN	O
of	IN	O
the	DT	O
thigh	NN	O
in	IN	O
infants	NNS	O
or	CC	O
into	IN	O
the	DT	O
deltoid	JJ	O
muscle	NN	O
(	(	O
upper	JJ	O
arm	NN	O
)	)	O
in	IN	O
toddlers	NNS	O
,	,	O
adolescents	NNS	B-WHO
and	CC	I-WHO
adults	NNS	O-WHO
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
regimen	NNS	O
for	IN	O
TYGACIL	NNP	O
is	VBZ	O
an	DT	O
initial	JJ	O
dose	NN	O
of	IN	O
100	CD	B-DOS
mg	NN	B-UNIT
,	,	O
followed	VBN	O
by	IN	O
50	CD	B-DOS
mg	NNS	B-UNIT
every	DT	B-FREQ
12	CD	I-FREQ
hours	NNS	O-FREQ
.	.	O

The	DT	O
maximum	NN	O
recommended	VBD	O
dose	NN	O
is	VBZ	O
600	CD	B-DOS
mg	NN	B-UNIT
once	RB	B-FREQ
daily	RB	O-FREQ
.	.	O

The	DT	O
recommended	JJ	O
initiation	NN	O
of	IN	O
INVEGA	NNP	O
SUSTENNA®	NNP	O
is	VBZ	O
with	IN	O
a	DT	O
dose	NN	O
of	IN	O
234	CD	B-DOS
mg	NNS	B-UNIT
on	IN	O
treatment	NN	O
day	NN	O
1	CD	O
and	CC	O
156	CD	B-DOS
mg	NN	B-UNIT
one	CD	O
week	NN	O
later	RB	O
,	,	O
both	DT	O
administered	VBN	O
in	IN	O
the	DT	O
deltoid	JJ	O
muscle	NN	O
.	.	O

ASTEPRO	RB	O
0.1	CD	O
%	NN	O
,	,	O
1	CD	B-DOS
spray	NN	B-UNIT
per	IN	O
nostril	JJ	O
twice	JJ	B-FREQ
daily	RB	O-FREQ
.	.	O

Use	NNP	O
once	RB	B-FREQ
or	CC	O
twice	VB	B-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
for	IN	O
up	IN	B-DUR
to	TO	I-DUR
7	CD	I-DUR
days	NNS	O-DUR
as	RB	O
needed	VBN	O
to	TO	O
relieve	VB	O
external	JJ	O
vulvar	NN	O
itching	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
ZELBORAF	NNP	O
is	VBZ	O
960	CD	B-DOS
mg	NN	B-UNIT
(	(	O
four	CD	B-DOS
240	CD	O-DOS
mg	NNS	B-UNIT
tablets	NNS	O-UNIT
)	)	O
orally	RB	O
every	DT	B-FREQ
12	CD	I-FREQ
hours	NNS	O-FREQ
with	IN	O
or	CC	O
without	IN	O
a	DT	O
meal	NN	O
.	.	O

Usual	JJ	O
dose	NN	O
:	:	O
Pyrazinamide	NNP	O
is	VBZ	O
administered	VBN	O
orally	RB	O
,	,	O
15	CD	B-DOS
to	TO	O
30	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
kg	NNS	O
once	RB	B-FREQ
daily	RB	O-FREQ
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
GENVOYA	NNP	O
is	VBZ	O
one	CD	B-DOS
tablet	NN	B-UNIT
taken	VBN	O
orally	RB	O
once	RB	B-FREQ
daily	JJ	O-FREQ
with	IN	O
food	NN	O
in	IN	O
adults	NNS	B-WHO
and	CC	I-WHO
pediatric	JJ	I-WHO
patients	NNS	I-WHO
12	CD	I-WHO
years	NNS	I-WHO
of	IN	I-WHO
age	NN	I-WHO
and	CC	I-WHO
older	JJR	I-WHO
with	IN	I-WHO
body	NN	I-WHO
weight	NN	I-WHO
at	IN	I-WHO
least	JJS	O-WHO
35	CD	O
kg	NN	O
and	CC	O
creatinine	JJ	O
clearance	NN	O
greater	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
30	CD	B-DOS
mL	NNS	B-UNIT
per	IN	O
minute	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
JARDIANCE	NNP	O
is	VBZ	O
10	CD	B-DOS
mg	NN	B-UNIT
once	RB	B-FREQ
daily	RB	O-FREQ
in	IN	O
the	DT	O
morning	NN	O
,	,	O
taken	VBN	O
with	IN	O
or	CC	O
without	IN	O
food	NN	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
is	VBZ	O
one	CD	B-DOS
ANDRODERM	NNP	O
4	CD	B-DOS
mg	NN	B-UNIT
/	NNP	B-FREQ
day	NN	O-FREQ
system	NN	O
(	(	O
not	RB	O
two	CD	B-DOS
2	CD	O-DOS
mg	NNS	B-UNIT
/	JJ	B-FREQ
day	NN	O-FREQ
systems	NNS	O
)	)	O
applied	VBD	O
nightly	RB	O
for	IN	O
24	CD	O
hours	NNS	O
,	,	O
delivering	VBG	O
approximately	RB	O
4	CD	B-DOS
mg	NNS	B-UNIT
of	IN	O
testosterone	NN	O
per	IN	B-FREQ
day	NN	O-FREQ
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
Qutenza	NNP	O
is	VBZ	O
a	DT	O
single	JJ	B-DOS
,	,	O
60	CD	O
-	:	O
minute	NN	O
application	NN	O
of	IN	O
up	IN	O
to	TO	O
four	CD	O
patches	NNS	O
.	.	O

Adults	NNS	B-WHO
and	CC	I-WHO
pediatric	JJ	I-WHO
patients	NNS	I-WHO
over	IN	I-WHO
12	CD	I-WHO
years	NNS	I-WHO
of	IN	I-WHO
age	NN	O-WHO
:	:	O
One	CD	B-DOS
or	CC	O
two	CD	B-DOS
tablets	NNS	B-UNIT
every	DT	B-FREQ
12	CD	I-FREQ
hours	NNS	O-FREQ
not	RB	O
to	TO	O
exceed	VB	O
4	CD	B-DOS
tablets	NNS	B-UNIT
in	IN	O
24	CD	O
hours	NNS	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
8	CD	B-DOS
mg	NN	B-UNIT
orally	RB	O
once	RB	B-FREQ
daily	JJ	O-FREQ
with	IN	O
a	DT	O
meal	NN	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
TrophAmine	NNP	O
is	VBZ	O
2	CD	B-DOS
to	TO	O
2.5	CD	B-DOS
grams	NNS	B-UNIT
of	IN	O
amino	JJ	O
acids	NNS	O
per	IN	O
kilogram	NN	O
of	IN	O
body	NN	O
weight	JJ	O
per	IN	B-FREQ
day	NN	O-FREQ
(	(	O
2	CD	B-DOS
to	TO	O
2.5	CD	B-DOS
g	NNS	B-UNIT
/	JJ	O
kg	JJ	O
/	NNP	B-FREQ
day	NN	O-FREQ
)	)	O
for	IN	O
infants	NNS	B-WHO
up	RB	I-WHO
to	TO	I-WHO
10	CD	I-WHO
kilograms	NNS	O-WHO
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
for	IN	O
REMERON	NNP	O
(	(	O
mirtazapine	NN	O
)	)	O
Tablets	NNPS	O
is	VBZ	O
15	CD	B-DOS
mg	JJ	B-UNIT
/	NNP	B-FREQ
day	NN	O-FREQ
,	,	O
administered	VBN	O
in	IN	O
a	DT	O
single	JJ	B-DOS
dose	NN	B-UNIT
,	,	O
preferably	RB	O
in	IN	O
the	DT	O
evening	NN	O
prior	RB	O
to	TO	O
sleep	VB	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
Aveed	NNP	O
is	VBZ	O
3	CD	B-DOS
mL	NN	B-UNIT
(	(	O
750	CD	B-DOS
mg	NN	B-UNIT
)	)	O
injected	VBD	O
intramuscularly	RB	O
,	,	O
followed	VBN	O
by	IN	O
3	CD	B-DOS
mL	NNS	B-UNIT
(	(	O
750	CD	B-DOS
mg	NN	B-UNIT
)	)	O
injected	VBD	O
after	IN	O
4	CD	O
weeks	NNS	O
,	,	O
then	RB	O
3	CD	B-DOS
mL	NNS	B-UNIT
(	(	O
750	CD	B-DOS
mg	NN	B-UNIT
)	)	O
injected	VBD	O
every	DT	B-FREQ
10	CD	I-FREQ
weeks	NNS	O-FREQ
thereafter	RB	O
.	.	O

The	DT	O
usual	JJ	O
dosage	NN	O
range	NN	O
studied	VBN	O
in	IN	O
clinical	JJ	O
trials	NNS	O
was	VBD	O
180	CD	B-DOS
mg	NN	B-UNIT
to	TO	O
480	CD	B-DOS
mg	NNS	B-UNIT
once	RB	B-FREQ
daily	RB	O-FREQ
.	.	O

Adults	NNS	B-WHO
and	CC	I-WHO
pediatric	JJ	I-WHO
patients	NNS	I-WHO
12	CD	I-WHO
years	NNS	I-WHO
of	IN	I-WHO
age	NN	I-WHO
and	CC	I-WHO
older	JJR	I-WHO
with	IN	I-WHO
body	NN	I-WHO
weight	NN	I-WHO
at	IN	I-WHO
least	JJS	I-WHO
40	CD	I-WHO
kg	NN	O-WHO
(	(	O
at	IN	O
least	JJS	O
88	CD	O
lbs	NN	O
)	)	O
The	DT	O
dose	NN	O
of	IN	O
ATRIPLA	NNP	O
is	VBZ	O
one	CD	B-DOS
tablet	NN	B-UNIT
once	IN	B-FREQ
daily	JJ	O-FREQ
taken	VBN	O
orally	RB	O
on	IN	O
an	DT	O
empty	JJ	O
stomach	NN	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
ACTEMRA	NNP	O
for	IN	O
adult	NN	B-WHO
patients	NNS	O
given	VBN	O
as	IN	O
a	DT	O
60	CD	B-DOS
-	:	O
minute	NN	O
single	JJ	O
intravenous	JJ	O
drip	NN	O
infusion	NN	O
is	VBZ	O
4	CD	B-DOS
mg	NN	B-UNIT
per	IN	O
kg	NN	O
every	DT	B-FREQ
4	CD	I-FREQ
weeks	NNS	O-FREQ
followed	VBN	O
by	IN	O
an	DT	O
increase	NN	O
to	TO	O
8	CD	B-DOS
mg	NNS	B-UNIT
per	IN	O
kg	NN	O
every	DT	B-FREQ
4	CD	I-FREQ
weeks	NNS	O-FREQ
based	VBN	O
on	IN	O
clinical	JJ	O
response	NN	O
.	.	O

One	CD	B-DOS
SITAVIG	NNP	O
50	CD	B-DOS
mg	NN	B-UNIT
buccal	JJ	I-UNIT
tablet	NN	O-UNIT
should	MD	O
be	VB	O
applied	VBN	O
as	IN	O
a	DT	O
single	JJ	B-DOS
dose	NN	B-UNIT
to	TO	O
the	DT	O
upper	JJ	O
gum	NN	O
region	NN	O
(	(	O
canine	JJ	O
fossa	NN	O
)	)	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
Gadavist	NNP	O
for	IN	O
adult	NN	B-WHO
and	CC	I-WHO
pediatric	JJ	I-WHO
patients	NNS	O-WHO
(	(	O
including	VBG	O
term	NN	O
neonates	NNS	O
)	)	O
is	VBZ	O
0.1	CD	B-DOS
mL	NN	B-UNIT
/	NNP	O
kg	VBZ	O
body	NN	O
weight	NN	O
(	(	O
0.1	CD	O
mmol	NN	O
/	NNP	O
kg	NN	O
)	)	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
REMICADE	NNP	O
is	VBZ	O
5	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
kg	VB	O
given	VBN	O
as	IN	O
an	DT	O
intravenous	JJ	O
induction	NN	O
regimen	NNS	O
at	IN	O
0	CD	O
,	,	O
2	CD	O
and	CC	O
6	CD	O
weeks	NNS	O
followed	VBN	O
by	IN	O
a	DT	O
maintenance	NN	O
regimen	NN	O
of	IN	O
5	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
kg	NN	O
every	DT	B-FREQ
8	CD	I-FREQ
weeks	NNS	O-FREQ
thereafter	RB	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
adults	NNS	B-WHO
with	IN	I-WHO
moderately	RB	I-WHO
to	TO	I-WHO
severely	RB	I-WHO
active	JJ	I-WHO
Crohn	NNP	I-WHO
's	POS	I-WHO
disease	NN	O-WHO
or	CC	O
fistulizing	VBG	O
Crohn	NNP	O
's	POS	O
disease	NN	O
.	.	O

The	DT	O
maximum	JJ	O
single	JJ	O
recommended	VBD	O
dose	NN	O
of	IN	O
ALSUMA	NNP	O
is	VBZ	O
6	CD	B-DOS
mg	NN	B-UNIT
injected	VBD	O
subcutaneously	RB	O
.	.	O

The	DT	O
recommended	JJ	O
initial	JJ	O
dose	NN	O
is	VBZ	O
750	CD	B-DOS
mg	JJ	B-UNIT
daily	RB	B-FREQ
in	IN	O
divided	JJ	O
doses	NNS	O
.	.	O

The	DT	O
average	JJ	O
protective	JJ	O
dose	NN	O
of	IN	O
vitamin	NN	O
C	NNP	O
for	IN	O
adults	NNS	B-WHO
is	VBZ	O
70	CD	B-DOS
to	TO	O
150	CD	B-DOS
mg	NNS	B-UNIT
daily	RB	B-FREQ
.	.	O

The	DT	O
recommended	JJ	O
starting	NN	O
schedule	NN	O
for	IN	O
induction	NN	O
is	VBZ	O
1.25	CD	B-DOS
mg	NN	B-UNIT
/	NN	O
m²administered	VBD	O
subcutaneously	RB	O
twice	JJ	B-FREQ
daily	RB	O-FREQ
for	IN	O
14	CD	B-DUR
consecutive	JJ	I-DUR
days	NNS	O-DUR
every	DT	B-FREQ
28	CD	I-FREQ
days	NNS	O-FREQ
,	,	O
over	IN	O
a	DT	O
28	CD	O
-	:	O
day	NN	O
cycle	NN	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
is	VBZ	O
1.34	CD	B-DOS
mg	NN	B-UNIT
(	(	O
1	CD	B-DOS
/	RB	O
2	CD	B-DOS
/	JJ	O
18	CD	B-DOS
tablet	NN	B-UNIT
)	)	O
twice	RB	B-FREQ
daily	RB	O-FREQ
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
EXONDYS	NNP	O
51	CD	O
is	VBZ	O
30	CD	B-DOS
milligrams	NNS	B-UNIT
per	IN	O
kilogram	NN	O
administered	VBN	O
once	RB	B-FREQ
weekly	JJ	O-FREQ
as	IN	O
a	DT	O
35	CD	O
to	TO	O
60	CD	O
minute	NN	O
intravenous	JJ	O
infusion	NN	O
.	.	O

The	DT	O
starting	VBG	O
dose	NN	O
should	MD	O
be	VB	O
12.5	CD	B-DOS
mg	JJ	B-UNIT
per	IN	B-FREQ
day	NN	O-FREQ
given	VBN	O
once	RB	B-FREQ
in	IN	O
the	DT	O
morning	NN	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
IXEMPRA	NNP	O
is	VBZ	O
40	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
m²	NN	O
administered	VBD	O
intravenously	RB	O
over	IN	O
3	CD	O
hours	NNS	O
every	DT	B-FREQ
3	CD	I-FREQ
weeks	NNS	O-FREQ
.	.	O

Recommended	VBN	O
starting	JJ	O
dosage	NN	O
is	VBZ	O
5	CD	B-DOS
mcg	JJ	B-UNIT
daily	RB	B-FREQ
.	.	O

The	DT	O
recommended	JJ	O
initial	JJ	O
dose	NN	O
for	IN	O
adults	NNS	B-WHO
is	VBZ	O
1	CD	B-DOS
mg	NN	B-UNIT
at	IN	O
bedtime	NN	O
;	:	O
however	RB	O
,	,	O
some	DT	O
patients	NNS	O
may	MD	O
need	VB	O
a	DT	O
2	CD	B-DOS
mg	NN	B-UNIT
dose	NN	O-UNIT
.	.	O

The	DT	O
starting	VBG	O
dose	NN	O
of	IN	O
ADLYXIN	NNP	O
is	VBZ	O
10	CD	B-DOS
mcg	NN	B-UNIT
subcutaneously	RB	O
once	RB	B-FREQ
daily	JJ	O-FREQ
for	IN	O
14	CD	B-DUR
days	NNS	O-DUR
.	.	O

Usual	JJ	O
Adult	NNP	B-WHO
Dose	NNP	O
:	:	O
One	CD	B-DOS
teaspoonful	NN	B-UNIT
(	(	O
5	CD	B-DOS
mL	NN	B-UNIT
)	)	O
after	IN	O
meals	NNS	O
and	CC	O
at	IN	O
bedtime	NN	O
,	,	O
not	RB	O
less	JJR	O
than	IN	O
4	CD	O
hours	NNS	O
apart	RB	O
(	(	O
not	RB	O
to	TO	O
exceed	VB	O
6	CD	B-DOS
teaspoonfuls	NNS	B-UNIT
in	IN	O
a	DT	O
24	CD	O
hour	NN	O
period	NN	O
)	)	O
.	.	O

For	IN	O
adults	NNS	B-WHO
,	,	O
the	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
of	IN	O
NASAREL	NNP	O
is	VBZ	O
2	CD	B-DOS
sprays	NNS	B-UNIT
(	(	O
58	CD	B-DOS
mcg	NN	B-UNIT
)	)	O
in	IN	O
each	DT	O
nostril	NN	O
2	CD	B-FREQ
times	NNS	I-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
(	(	O
total	JJ	O
dose	RB	O
232	CD	B-DOS
mcg	JJ	B-UNIT
/	NNP	B-FREQ
day	NN	O-FREQ
)	)	O
:	:	O
the	DT	O
effect	NN	O
should	MD	O
be	VB	O
assessed	VBN	O
in	IN	O
4	CD	B-DUR
to	TO	I-DUR
7	CD	I-DUR
days	NNS	O-DUR
.	.	O

KYBELLA	NNP	O
is	VBZ	O
injected	VBN	O
into	IN	O
subcutaneous	JJ	O
fat	JJ	O
tissue	NN	O
in	IN	O
the	DT	O
submental	JJ	O
area	NN	O
using	VBG	O
an	DT	O
area	NN	O
-	:	O
adjusted	VBN	O
dose	NN	O
of	IN	O
2	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
cm²	NN	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
of	IN	O
Kineret	NNP	O
is	VBZ	O
1	CD	B-DOS
-	:	O
2	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
kg	NN	O
for	IN	O
NOMID	NNP	B-WHO
patients	NNS	O-WHO
.	.	O

A	DT	O
thin	JJ	O
layer	NN	O
of	IN	O
Cormax	NNP	O
Ointment	NNP	O
should	MD	O
be	VB	O
applied	VBN	O
with	IN	O
gentle	JJ	O
rubbing	VBG	O
to	TO	O
the	DT	O
affected	JJ	O
skin	JJ	O
area	NN	O
twice	RB	B-FREQ
daily	RB	O-FREQ
,	,	O
once	RB	O
in	IN	O
the	DT	O
morning	NN	O
and	CC	O
once	RB	O
at	IN	O
night	NN	O
.	.	O

IFEX	NNP	O
(	(	O
ifosfamide	NN	O
)	)	O
should	MD	O
be	VB	O
administered	VBN	O
intravenously	RB	O
at	IN	O
a	DT	O
dose	NN	O
of	IN	O
1.2	CD	B-DOS
g	NNS	B-UNIT
/	JJ	O
m²	JJ	O
per	IN	B-FREQ
day	NN	O-FREQ
for	IN	O
5	CD	B-DUR
consecutive	JJ	I-DUR
days	NNS	O-DUR
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
PROVIGIL	NNP	O
for	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
narcolepsy	JJ	I-WHO
or	CC	I-WHO
OSA	NNP	O-WHO
is	VBZ	O
200	CD	B-DOS
mg	NN	B-UNIT
taken	VBN	O
orally	RB	O
once	RB	B-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
as	IN	O
a	DT	O
single	JJ	B-DOS
dose	NN	B-UNIT
in	IN	O
the	DT	O
morning	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
IMBRUVICA	NNP	O
for	IN	O
MCL	NNP	O
is	VBZ	O
560	CD	B-DOS
mg	NN	B-UNIT
(	(	O
four	CD	B-DOS
140	CD	O-DOS
mg	NN	B-UNIT
capsules	NNS	O-UNIT
)	)	O
orally	RB	O
once	RB	B-FREQ
daily	JJ	O-FREQ
.	.	O

The	DT	O
recommended	JJ	O
oral	JJ	O
dose	NN	O
of	IN	O
RETROVIR	NNP	O
is	VBZ	O
300	CD	B-DOS
mg	JJ	B-UNIT
twice	RB	B-FREQ
daily	RB	O-FREQ
in	IN	O
combination	NN	O
with	IN	O
other	JJ	O
antiretroviral	JJ	O
agents	NNS	O
.	.	O

Donnatal®	NNP	O
Tablets	NNP	O
-	:	O
Adults	NNS	O
:	:	O
One	CD	B-DOS
or	CC	O
two	CD	B-DOS
Donnatal®	NNP	B-UNIT
Tablets	NNPS	O-UNIT
three	CD	B-FREQ
or	CC	O
four	CD	B-FREQ
times	NNS	I-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
according	VBG	O
to	TO	O
condition	NN	O
and	CC	O
severity	NN	O
of	IN	O
symptoms	NNS	O
.	.	O

Administer	NNP	O
CYMBALTA	NNP	O
at	IN	O
a	DT	O
total	JJ	O
dose	NN	O
of	IN	O
40	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	B-FREQ
day	NN	O-FREQ
(	(	O
given	VBN	O
as	IN	O
20	CD	B-DOS
mg	JJ	B-UNIT
twice	RB	B-FREQ
daily	RB	O-FREQ
)	)	O
to	TO	O
60	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	B-FREQ
day	NN	O-FREQ
(	(	O
given	VBN	O
either	DT	O
once	RB	B-FREQ
daily	JJ	O-FREQ
or	CC	O
as	IN	O
30	CD	B-DOS
mg	JJ	B-UNIT
twice	RB	B-FREQ
daily	RB	O-FREQ
)	)	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
PLETAL	NNP	O
is	VBZ	O
100	CD	B-DOS
mg	JJ	B-UNIT
twice	RB	B-FREQ
daily	RB	O-FREQ
taken	VBN	O
at	IN	O
least	JJS	O
half	PDT	O
an	DT	O
hour	NN	O
before	IN	O
or	CC	O
two	CD	O
hours	NNS	O
after	IN	O
breakfast	NN	O
and	CC	O
dinner	NN	O
.	.	O

Administer	RB	O
ABLAVAR	NNP	O
as	IN	O
an	DT	O
intravenous	JJ	O
bolus	NN	O
injection	NN	O
,	,	O
manually	RB	O
or	CC	O
by	IN	O
power	NN	O
injection	NN	O
,	,	O
at	IN	O
a	DT	O
dose	NN	O
of	IN	O
0.12	CD	B-DOS
mL	NNS	B-UNIT
/	JJ	O
kg	FW	O
body	NN	O
weight	NN	O
(	(	O
0.03	CD	O
mmol	NN	O
/	NNP	O
kg	NN	O
)	)	O
over	IN	O
a	DT	O
period	NN	O
of	IN	O
time	NN	O
up	IN	O
to	TO	O
30	CD	O
seconds	NNS	O
followed	VBN	O
by	IN	O
a	DT	O
25	CD	B-DOS
-	:	O
30	CD	B-DOS
mL	NN	B-UNIT
normal	JJ	O
saline	JJ	O
flush	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
OPDIVO	NNP	O
is	VBZ	O
240	CD	B-DOS
mg	NN	B-UNIT
administered	VBN	O
as	IN	O
an	DT	O
intravenous	JJ	O
infusion	NN	O
over	IN	O
60	CD	O
minutes	NNS	O
every	DT	B-FREQ
2	CD	I-FREQ
weeks	NNS	O-FREQ
until	IN	O
disease	JJ	O
progression	NN	O
or	CC	O
unacceptable	JJ	O
toxicity	NN	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
COLCRYS	NNP	O
for	IN	O
prophylaxis	NN	O
of	IN	O
gout	NN	O
flares	NNS	O
for	IN	O
adults	NNS	B-WHO
and	CC	I-WHO
adolescents	NNS	I-WHO
older	JJR	I-WHO
than	IN	O-WHO
16	CD	HO
years	NNS	B-WHO
of	IN	I-WHO
age	NN	O-WHO
is	VBZ	O
0.6	CD	B-DOS
mg	NN	B-UNIT
once	RB	B-FREQ
or	CC	O
twice	RB	B-FREQ
daily	RB	O-FREQ
.	.	O

One	CD	B-DOS
drop	NN	B-UNIT
of	IN	O
ILEVRO	NNP	O
(	(	O
nepafenac	JJ	O
ophthalmic	JJ	O
suspension	NN	O
)	)	O
,	,	O
0.3	CD	O
%	NN	O
should	MD	O
be	VB	O
applied	VBN	O
to	TO	O
the	DT	O
affected	JJ	O
eye	NN	O
one	CD	B-FREQ
-	:	O
time	NN	B-FREQ
-	:	O
daily	JJ	B-FREQ
beginning	VBG	O
1	CD	O
day	NN	O
prior	RB	O
to	TO	O
cataract	VB	O
surgery	NN	O
,	,	O
continued	VBD	O
on	IN	O
the	DT	O
day	NN	O
of	IN	O
surgery	NN	O
and	CC	O
through	IN	O
the	DT	O
first	JJ	O
2	CD	O
weeks	NNS	O
of	IN	O
the	DT	O
postoperative	JJ	O
period	NN	O
.	.	O

The	DT	O
dose	NN	O
of	IN	O
Endometrin	NNP	O
is	VBZ	O
100	CD	B-DOS
mg	NN	B-UNIT
administered	VBN	O
vaginally	RB	O
two	CD	O
or	CC	O
three	CD	B-FREQ
times	NNS	I-FREQ
daily	RB	O-FREQ
starting	VBG	O
the	DT	O
day	NN	O
after	IN	O
oocyte	JJ	O
retrieval	NN	O
and	CC	O
continuing	VBG	O
for	IN	O
up	IN	B-DUR
to	TO	I-DUR
10	CD	I-DUR
weeks	NNS	O-DUR
total	JJ	O
duration	NN	O
.	.	O

The	DT	O
recommended	JJ	O
bolus	NN	O
dose	NN	O
for	IN	O
activated	JJ	O
DEFINITY	NNP	O
is	VBZ	O
10	CD	B-DOS
microliters	NNS	B-UNIT
(	(	O
microL	NN	O
)	)	O
/	VBZ	O
kg	NN	O
of	IN	O
the	DT	O
activated	JJ	O
product	NN	O
by	IN	O
intravenous	JJ	O
bolus	NN	O
injection	NN	O
within	IN	O
30	CD	O
-	:	O
60	CD	O
seconds	NNS	O
,	,	O
followed	VBN	O
by	IN	O
a	DT	O
10	CD	B-DOS
mL	NN	B-UNIT
saline	NN	O
flush	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
BIVIGAM	NNP	O
for	IN	O
replacement	NN	O
therapy	NN	O
in	IN	O
primary	JJ	O
humoral	JJ	O
immunodeficiency	NN	O
(	(	O
PI	NNP	O
)	)	O
is	VBZ	O
300	CD	B-DOS
to	TO	O
800	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
kg	FW	O
body	NN	O
weight	NN	O
administered	VBN	O
every	DT	B-FREQ
3	CD	O-FREQ
to	TO	O
4	CD	B-FREQ
weeks	NNS	O-FREQ
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
of	IN	O
Duraclon	NNP	O
for	IN	O
continuous	JJ	O
epidural	JJ	O
infusion	NN	O
is	VBZ	O
30	CD	B-DOS
mcg	NN	B-UNIT
/	NNP	B-FREQ
hr	NN	O-FREQ
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
for	IN	O
both	DT	O
adults	NNS	B-WHO
and	CC	I-WHO
pediatric	JJ	I-WHO
patients	NNS	I-WHO
6	CD	I-WHO
years	NNS	I-WHO
of	IN	I-WHO
age	NN	I-WHO
and	CC	I-WHO
older	JJR	O-WHO
is	VBZ	O
1	CD	B-DOS
single	JJ	O-DOS
-	:	O
use	NN	B-DOS
ampule	NN	B-UNIT
(	(	O
300	CD	B-DOS
mg	NN	B-UNIT
)	)	O
administered	VBD	O
BID	NNP	O
for	IN	O
28	CD	B-DUR
days	NNS	O-DUR
.	.	O

Initial	JJ	O
200	CD	B-DOS
-	:	O
400	CD	B-DOS
mg	JJ	B-UNIT
daily	RB	B-FREQ
in	IN	O
two	CD	B-DOS
divided	JJ	B-UNIT
doses	NNS	O-UNIT
,	,	O
with	IN	O
meals	NNS	O
or	CC	O
milk	NN	O
,	,	O
gradually	RB	O
increasing	VBG	O
when	WRB	O
necessary	JJ	O
to	TO	O
full	JJ	O
maintenance	NN	O
dosage	NN	O
in	IN	O
one	CD	O
week	NN	O
.	.	O

Adacel	NNP	O
vaccine	NN	O
is	VBZ	O
administered	VBN	O
as	IN	O
a	DT	O
single	JJ	B-DOS
0.5	CD	O-DOS
mL	NN	B-UNIT
intramuscular	JJ	O
injection	NN	B-UNIT
into	IN	O
the	DT	O
deltoid	JJ	O
muscle	NN	O
of	IN	O
the	DT	O
upper	JJ	O
arm	NN	O
.	.	O

The	DT	O
recommended	VBN	O
initial	JJ	O
total	JJ	O
daily	JJ	B-FREQ
dose	NN	O
of	IN	O
FOSRENOL	NNP	O
is	VBZ	O
1500	CD	B-DOS
mg	NN	B-UNIT
.	.	O

The	DT	O
recommended	VBN	O
adult	NN	B-WHO
oral	JJ	O
dosage	NN	O
for	IN	O
duodenal	JJ	O
ulcer	NN	O
is	VBZ	O
1	CD	B-DOS
g	NN	B-UNIT
(	(	O
10	CD	B-DOS
mL	NN	B-UNIT
/	VBD	O
2	CD	B-DOS
teaspoons	NNS	B-UNIT
)	)	O
four	CD	B-FREQ
times	NNS	I-FREQ
per	IN	I-FREQ
day	NN	O-FREQ
.	.	O

The	DT	O
dose	NN	O
is	VBZ	O
one	CD	B-DOS
drop	NN	B-UNIT
of	IN	O
TIMOPTIC	NNP	O
-	:	O
XE	NN	O
(	(	O
either	CC	O
0.25	CD	O
%	NN	O
or	CC	O
0.5	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
affected	JJ	O
eye	NN	O
(	(	O
s	JJ	O
)	)	O
once	RB	B-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
.	.	O

The	DT	O
recommended	VBN	O
adult	NN	B-WHO
oral	JJ	O
dosage	NN	O
of	IN	O
ZOFRAN	NNP	O
is	VBZ	O
24	CD	B-DOS
mg	NN	B-UNIT
given	VBN	O
as	IN	O
three	CD	B-DOS
8	CD	O-DOS
-	:	O
mg	NN	B-UNIT
tablets	NNS	O-UNIT
administered	VBD	O
30	CD	O
minutes	NNS	O
before	IN	O
the	DT	O
start	NN	O
of	IN	O
single	JJ	O
-	:	O
day	NN	O
highly	RB	O
emetogenic	JJ	O
chemotherapy	NN	O
,	,	O
including	VBG	O
cisplatin	NN	O
≥	VBD	O
50	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
m	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
Gammaplex	NNP	O
for	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
PI	NNP	O-WHO
is	VBZ	O
300	CD	B-DOS
to	TO	O
800	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
kg	NN	O
(	(	O
6	CD	B-DOS
to	TO	O
16	CD	B-DOS
mL	NNS	B-UNIT
/	NNP	O
kg	NN	O
)	)	O
,	,	O
administered	VBN	O
every	DT	B-FREQ
3	CD	O-FREQ
to	TO	O
4	CD	B-FREQ
weeks	NNS	O-FREQ
.	.	O

The	DT	O
usual	JJ	O
dose	NN	O
is	VBZ	O
1	CD	B-DOS
to	TO	O
3	CD	B-DOS
mg	NNS	B-UNIT
administered	VBN	O
under	IN	O
careful	JJ	O
monitoring	NN	O
,	,	O
such	JJ	O
as	IN	O
electrocardiography	NN	O
and	CC	O
central	JJ	O
venous	JJ	O
pressure	NN	O
.	.	O

Apply	VB	O
a	DT	O
thin	JJ	O
film	NN	O
of	IN	O
0.1	CD	O
%	NN	O
HALOG	NNP	O
OINTMENT	NNP	O
(	(	O
Halcinonide	NNP	O
Ointment	NNP	O
,	,	O
USP	NNP	O
)	)	O
to	TO	O
the	DT	O
affected	JJ	O
area	NN	O
two	CD	B-FREQ
to	TO	O
three	CD	B-FREQ
times	NNS	I-FREQ
daily	RB	O-FREQ
.	.	O

Most	JJS	B-WHO
patients	NNS	O-WHO
require	VBP	O
60	CD	B-DOS
to	TO	O
120	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	B-FREQ
day	NN	O-FREQ
.	.	O

Initiate	NNP	O
treatment	NN	O
with	IN	O
one	CD	B-DOS
0.1	CD	O-DOS
mg	NN	B-UNIT
tablet	NN	O-UNIT
at	IN	O
bedtime	NN	O
.	.	O

Buprenorphine	NNP	O
and	CC	O
naloxone	RB	O
sublingual	JJ	O
tablets	NNS	O
are	VBP	O
administered	VBN	O
sublingually	RB	O
as	IN	O
a	DT	O
single	JJ	B-DOS
daily	JJ	B-FREQ
dose	NN	B-UNIT
.	.	O

The	DT	O
usual	JJ	O
starting	NN	O
dose	NN	O
is	VBZ	O
5	CD	B-DOS
mg	NN	B-UNIT
once	RB	B-FREQ
daily	RB	O-FREQ
.	.	O

RISPERDAL®	NNP	O
CONSTA®	NNP	O
should	MD	O
be	VB	O
administered	VBN	O
every	DT	B-FREQ
2	CD	I-FREQ
weeks	NNS	O-FREQ
by	IN	O
deep	JJ	O
intramuscular	NN	O
(	(	O
IM	NNP	O
)	)	O
deltoid	NN	O
or	CC	O
gluteal	JJ	O
injection	NN	O
.	.	O

GEODON	NNP	O
Capsules	NNP	O
should	MD	O
be	VB	O
administered	VBN	O
at	IN	O
an	DT	O
initial	JJ	O
daily	JJ	B-FREQ
dose	NN	O
of	IN	O
20	CD	B-DOS
mg	JJ	B-UNIT
twice	RB	B-FREQ
daily	RB	O-FREQ
with	IN	O
food	NN	O
.	.	O

The	DT	O
usual	JJ	O
dose	NN	O
of	IN	O
VINCASAR	NNP	O
PFS	NNP	O
for	IN	O
adults	NNS	B-WHO
is	VBZ	O
1.4	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
m²	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
GYNAZOLE•1®	NNP	O
Butoconazole	NNP	O
Nitrate	NNP	O
Vaginal	NNP	O
Cream	NNP	O
USP	NNP	O
,	,	O
2	CD	O
%	NN	O
is	VBZ	O
one	CD	B-DOS
applicatorful	NN	B-UNIT
of	IN	O
cream	NN	O
(	(	O
approximately	RB	O
5	CD	B-DOS
grams	NNS	B-UNIT
of	IN	O
the	DT	O
cream	NN	O
)	)	O
intravaginally	RB	O
.	.	O

The	DT	O
usual	JJ	O
recommended	VBD	O
dose	NN	O
for	IN	O
initial	JJ	O
nasal	JJ	O
administration	NN	O
is	VBZ	O
1	CD	B-DOS
mg	NN	B-UNIT
(	(	O
1	CD	B-DOS
spray	NN	B-UNIT
in	IN	O
one	CD	O
nostril	NN	O
)	)	O
.	.	O

The	DT	O
recommended	JJ	O
treatment	NN	O
regimen	NNS	O
is	VBZ	O
20	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
mL	NN	O
VIRAZOLE	NNP	O
(	(	O
ribavirin	NN	O
)	)	O
as	IN	O
the	DT	O
starting	VBG	O
solution	NN	O
in	IN	O
the	DT	O
drug	NN	O
reservoir	NN	O
of	IN	O
the	DT	O
SPAG	NNP	O
-	:	O
2	CD	B-DOS
unit	NN	B-UNIT
,	,	O
with	IN	O
continuous	JJ	O
aerosol	NNS	O
administration	NN	O
for	IN	O
12	CD	O
-	:	O
18	CD	O
hours	NNS	O
per	IN	B-FREQ
day	NN	O-FREQ
for	IN	O
3	CD	B-DUR
to	TO	O
7	CD	B-DUR
days	NNS	O-DUR
.	.	O

The	DT	O
recommended	VBN	O
adult	NN	B-WHO
dose	NN	O
,	,	O
after	IN	O
reconstitution	NN	O
with	IN	O
oxidant	JJ	O
-	:	O
free	JJ	O
sodium	NN	O
pertechnetate	NN	O
Tc	NNP	O
99m	CD	O
,	,	O
is	VBZ	O
370	CD	B-DOS
to	TO	O
740	CD	B-DOS
megabecquerels	NNS	B-UNIT
(	(	O
10	CD	B-DOS
to	TO	O
20	CD	B-DOS
millicuries	NNS	B-UNIT
[	VBP	O
200	CD	B-DOS
μCi	JJ	B-UNIT
/	NNP	O
kg	NNP	O
]	NNP	O
)	)	O
by	IN	O
slow	JJ	O
intravenous	JJ	O
injection	NN	O
over	IN	O
a	DT	O
period	NN	O
of	IN	O
30	CD	O
seconds	NNS	O
.	.	O

The	DT	O
usual	JJ	O
dietary	JJ	O
potassium	NN	O
intake	NN	O
by	IN	O
the	DT	O
average	JJ	O
adult	NN	B-WHO
is	VBZ	O
50	CD	B-DOS
to	TO	O
100	CD	B-DOS
mEq	NNS	B-UNIT
per	IN	B-FREQ
day	NN	O-FREQ
.	.	O

For	IN	O
treatment	NN	O
of	IN	O
moderate	JJ	O
to	TO	O
severe	VB	O
vasomotor	NN	O
symptoms	NNS	O
or	CC	O
moderate	VB	O
to	TO	O
severe	VB	O
symptoms	NNS	O
of	IN	O
vulvar	NN	O
and	CC	O
vaginal	JJ	O
atrophy	NN	O
associated	VBN	O
with	IN	O
the	DT	O
menopause	NN	O
,	,	O
initiate	JJ	O
therapy	NN	O
with	IN	O
Estraderm	NNP	O
(	(	O
estradiol	FW	O
transdermal	NN	O
)	)	O
0.05	CD	O
applied	VBN	O
to	TO	O
the	DT	O
skin	NN	O
twice	RB	B-FREQ
weekly	RB	O-FREQ
.	.	O

The	DT	O
total	JJ	O
daily	JJ	B-FREQ
dosage	NN	O
is	VBZ	O
generally	RB	O
taken	VBN	O
at	IN	O
a	DT	O
single	JJ	O
time	NN	O
each	DT	O
morning	NN	O
with	IN	O
breakfast	NN	O
.	.	O

The	DT	O
recommended	VBN	O
adult	NN	B-WHO
intravenous	JJ	O
dosage	NN	O
of	IN	O
ZOFRAN	NNP	O
is	VBZ	O
three	CD	B-DOS
0.15	CD	O-DOS
-	:	O
mg	NN	B-UNIT
/	JJ	O
kg	NN	O
doses	VBZ	O
up	RP	O
to	TO	O
a	DT	O
maximum	NN	O
of	IN	O
16	CD	B-DOS
mg	NNS	B-UNIT
per	IN	O
dose	NN	O
.	.	O

The	DT	O
usual	JJ	O
adult	NN	B-WHO
dose	NN	O
is	VBZ	O
2	CD	B-DOS
caplets	NNS	B-UNIT
three	CD	B-FREQ
or	CC	O
four	CD	B-FREQ
times	NNS	I-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
BRISDELLE	NNP	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
moderate	JJ	O
to	TO	O
severe	VB	O
VMS	NNP	O
is	VBZ	O
7.5	CD	B-DOS
mg	NN	B-UNIT
once	RB	B-FREQ
daily	JJ	O-FREQ
,	,	O
at	IN	O
bedtime	NN	O
,	,	O
with	IN	O
or	CC	O
without	IN	O
food	NN	O
.	.	O

One	CD	B-DOS
tablet	NN	B-UNIT
is	VBZ	O
taken	VBN	O
every	DT	B-FREQ
day	NN	O-FREQ
,	,	O
at	IN	O
the	DT	O
same	JJ	O
time	NN	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dosage	NN	O
of	IN	O
RYTARY	NNP	O
in	IN	O
levodopa	JJ	O
-	:	O
naïve	NN	B-WHO
patients	NNS	O-WHO
is	VBZ	O
23.75	CD	B-DOS
mg	NN	B-UNIT
/	VBD	O
95	CD	B-DOS
mg	NN	B-UNIT
taken	VBN	O
orally	RB	O
three	CD	B-FREQ
times	NNS	I-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
for	IN	O
the	DT	O
first	JJ	O
3	CD	O
days	NNS	O
.	.	O

Dose	NNP	O
once	RB	B-FREQ
-	:	O
daily	NN	B-FREQ
.	.	O

The	DT	O
recommended	JJ	O
initial	JJ	O
dose	NN	O
is	VBZ	O
6.25	CD	B-DOS
mg	NN	B-UNIT
for	IN	O
women	NNS	B-WHO
and	CC	O
either	DT	O
6.25	CD	B-DOS
or	CC	O
12.5	CD	B-DOS
mg	NN	B-UNIT
for	IN	O
men	NNS	B-WHO
,	,	O
taken	VBN	O
only	RB	O
once	RB	B-FREQ
per	IN	I-FREQ
night	NN	O-FREQ
immediately	RB	O
before	IN	O
bedtime	NN	O
with	IN	O
at	IN	O
least	JJS	O
7	CD	O
-	:	O
8	CD	O
hours	NNS	O
remaining	VBG	O
before	IN	O
the	DT	O
planned	JJ	O
time	NN	O
of	IN	O
awakening	VBG	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
Calcium	NNP	O
Disodium	NNP	O
Versenate	NNP	O
for	IN	O
asymptomatic	JJ	O
adults	NNS	B-WHO
and	CC	I-WHO
pediatric	JJ	I-WHO
patients	NNS	I-WHO
whose	WP$	I-WHO
blood	JJ	I-WHO
lead	NN	I-WHO
level	NN	I-WHO
is	VBZ	O-WHO
<	JJ	O
70	CD	O
mcg	NN	O
/	NN	O
dl	NN	O
but	CC	O
>	$	O
20	CD	B-DOS
mcg	NN	B-UNIT
/	NN	O
dl	NN	O
(	(	O
World	NNP	O
Health	NNP	O
Organization	NNP	O
recommended	VBD	O
upper	JJ	O
allowable	JJ	O
level	NN	O
)	)	O
is	VBZ	O
1000	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
m2	NN	O
/	NNP	B-FREQ
day	NN	O-FREQ
whether	IN	O
given	VBN	O
intravenously	RB	O
or	CC	O
intramuscularly	RB	O
.	.	O

For	IN	O
adults	NNS	B-WHO
,	,	O
COLESTID	NNP	O
Tablets	NNP	O
are	VBP	O
recommended	VBN	O
in	IN	O
doses	NNS	O
of	IN	O
2	CD	B-DOS
to	TO	O
16	CD	B-DOS
grams	NNS	B-UNIT
/	JJ	B-FREQ
day	NN	O-FREQ
given	VBN	O
once	RB	O
or	CC	O
in	IN	O
divided	JJ	O
doses	NNS	O
.	.	O

The	DT	O
dose	JJ	O
range	NN	O
for	IN	O
LIVALO	NNP	O
is	VBZ	O
1	CD	B-DOS
to	TO	O
4	CD	B-DOS
mg	NNS	B-UNIT
orally	RB	O
once	RB	B-FREQ
daily	JJ	O-FREQ
at	IN	O
any	DT	O
time	NN	O
of	IN	O
the	DT	O
day	NN	O
with	IN	O
or	CC	O
without	IN	O
food	NN	O
.	.	O

For	IN	O
the	DT	O
clinical	JJ	O
dietary	JJ	O
management	NN	O
of	IN	O
the	DT	O
metabolic	JJ	O
processes	NNS	O
of	IN	O
OA	NNP	O
,	,	O
take	VBP	O
either	DT	O
one	CD	B-DOS
250	CD	O-DOS
mg	NN	B-UNIT
or	CC	O
one	CD	B-DOS
500	CD	O-DOS
mg	NN	B-UNIT
capsule	NN	O-UNIT
every	DT	B-FREQ
12	CD	I-FREQ
hours	NNS	O-FREQ
for	IN	O
500	CD	B-DOS
mg	NN	B-UNIT
to	TO	O
1000	CD	B-DOS
mg	NN	B-UNIT
total	JJ	O
daily	JJ	B-FREQ
consumption	NN	O
as	IN	O
directed	VBN	O
by	IN	O
a	DT	O
physician	NN	O
.	.	O

The	DT	O
usual	JJ	O
initial	JJ	O
antihypertensive	JJ	O
oral	JJ	O
dose	NN	O
of	IN	O
NORVASC	NNP	O
is	VBZ	O
5	CD	B-DOS
mg	NN	B-UNIT
once	RB	B-FREQ
daily	JJ	O-FREQ
,	,	O
and	CC	O
the	DT	O
maximum	JJ	O
dose	NN	O
is	VBZ	O
10	CD	B-DOS
mg	NN	B-UNIT
once	RB	B-FREQ
daily	RB	O-FREQ
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
GILOTRIF	NNP	O
is	VBZ	O
40	CD	B-DOS
mg	NN	B-UNIT
orally	RB	O
,	,	O
once	RB	B-FREQ
daily	JJ	O-FREQ
until	IN	O
disease	JJ	O
progression	NN	O
or	CC	O
no	DT	O
longer	RB	O
tolerated	VBN	O
by	IN	O
the	DT	O
patient	NN	O
.	.	O

The	DT	O
usual	JJ	O
initial	JJ	O
dosage	NN	O
is	VBZ	O
80	CD	B-DOS
mg	JJ	B-UNIT
Inderal	NNP	O
LA	NNP	O
once	RB	B-FREQ
daily	RB	O-FREQ
,	,	O
whether	IN	O
used	VBN	O
alone	RB	O
or	CC	O
added	VBN	O
to	TO	O
a	DT	O
diuretic	JJ	O
.	.	O

